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ABSTRACT 
 
In the acute setting of ischaemic stroke, two proven treatments are available: intravenous thrombolysis (iv-tPA) 
with alteplase and endovascular thrombectomy. The main aim of this thesis was to investigate the associations 
between symptom severity in the acute setting of ischaemic stroke and 
 
1) the presence of arterial occlusions and 
2) long-term functional outcome assessed at 3 months. 
 
The first 3 studies were based on patients registered in the large Safe Implementation of Treatments in Stroke - 
International Stroke Thrombolysis Register (SITS-ISTR). In the final project, conceptually separated from the 
first 3 studies, we aimed to investigate a novel method for assessing 3-month functional outcome after acute 
stroke. 
 
Study 1. We aimed at finding thresholds for baseline stroke severity as measured by National Institutes of 
Health Stroke Scale (NIHSS) scores that predicted long-term functional outcome and baseline arterial 
occlusion. We analysed 44 331 iv-tPA treated ischaemic stroke patients with available functional outcome 
assessed by the modified Rankin Scale (mRS) at three-months and 11 632 patients with available computed 
tomography/magnetic resonance angiography data at baseline. For functional independency (mRS 0-2), NIHSS 
scores of 12 [area under the curve (AUC) 0.775] and for baseline arterial occlusion, NIHSS scores of 11 (AUC 
0.678) were optimal threshold values. NIHSS thresholds decreased with time from stroke onset to imaging, 
with 2–3 points, respectively, if time to imaging exceeded three-hours. We concluded that an NIHSS threshold 
of 9 or 10 points could be considered in the pre-hospital selection of patients for immediate transfer to centres 
with arterial imaging and availability of endovascular thrombectomy. 
 
Study 2. ASTRAL and DRAGON are two recently developed scores for predicting long-term functional 
outcome after acute stroke in unselected acute ischaemic stroke patients and in patients treated with iv-tPA, 
respectively. We aimed to perform external validation of these scores. We calculated the ASTRAL and 
DRAGON scores in 36131 and 33716 iv-tPA treated patients, respectively, registered in the SITS-ISTR 
between 2003 and 2013. The proportion of patients with death or dependency at 3 months (mRS 3-6) was 
observed for each score point and compared with the predicted proportion according to the risk scores. 
Predictive performance was assessed using the AUC of the receiver operating characteristic. The ASTRAL 
showed an AUC of 0.790 (95% CI, 0.786–0.795) and the DRAGON an AUC of 0.774 (95% CI, 0.769–0.779). 
We concluded that the ASTRAL and DRAGON scores show an acceptable predictive performance and may 
have a role for prognostication of outcome after acute ischaemic stroke. 
 
Study 3.  We aimed to assess the predictive value of various models based on baseline NIHSS sub-items, 
ranging from simple to more complex models, for predicting large arterial occlusions (LAO) in anterior 
circulation stroke. Patients registered in the SITS-ISTR with clinically defined anterior circulation stroke, and 
available NIHSS and radiological arterial occlusion data were analysed. We compared 1975 patients harbouring 
an LAO with 2036 patients having no/distal occlusions. Using binary logistic regression, we developed models 
ranging from a simple 1 NIHSS-sub-item to full NIHSS-sub-items models. Sensitivities and specificities of the 
models for predicting LAO were examined. The model with highest predictive value included all NIHSS sub-
items as well as other relevant parameters for predicting LAO (AUC 0.78), yielding a sensitivity and specificity 
of 74% and 72% respectively. The simplest model included only deficits in arm motor-function (AUC 0.72) for 
predicting LAO, yielding a sensitivity and specificity of 69% and 70% respectively. Differences between the 
models were not large. We concluded that assessing grade of arm-dysfunction along with an established stroke-
diagnosis model may serve a surrogate measure of LAO status, thereby assisting in triage decisions. 
 
Study 4.  Assessment of long-term functional outcome is lacking in many settings. We aimed to investigate 
whether automatic assessment of the mRS based on a mobile phone questionnaire may serve as an alternative 
to mRS assessments at clinical visits after stroke. We enrolled 62 acute stroke patients admitted to our stroke 
unit during March to May 2014. Forty- eight patients completed the study. During the hospital stay, patients 
and/or caregivers were equipped with a mobile phone application in their personal mobile phones. Three months 
after inclusion, the mobile phone application automatically prompted the study participants to answer an mRS 
questionnaire in the mobile phones. A few days later, a study personnel performed a clinical visit mRS 
assessment. The 2 assessments were compared using quadratic weighing κ-statistics. We found a 62.5% 
agreement between clinical visit and mobile mRS assessment, weighted kappa 0.89 (95% CI 0.82–0.96), and 
unweighted kappa 0.53 (95% CI 0.36– 0.70). Mobile phone–based automatic assessments of mRS performed 
well in comparison with clinical visit mRS and may serve a supplementary role to traditional assessments, 
especially in settings where clinical follow-up visits are scarce because of economic and time-restraining 
factors.
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1 INTRODUCTION 
 
The World Health Organization (WHO) definition of stroke from the 1970s is 
the following: “Rapidly developing clinical signs of focal or global disturbance of 
cerebral function, lasting more than 24 hours or leading to death, with no 
apparent cause other than of vascular origin” (1). Patients with symptoms 
resolving within 24h are denoted as suffering from a transient ischaemic attack 
(TIA). 
This definition of stroke does not reveal the underlying pathophysiology. The 
proportion of stroke caused by cerebral infarction is 70-85%, while 15-30% is 
caused by intracerebral and subarachnoid haemorrhage (bleeding). Infarction is 
defined as irreversible cell death caused by ischaemia. Cerebral ischaemia 
denotes a state of insufficient blood flow to uphold the energetic requirements 
of the brain. This disruption of the blood flow is caused by obstruction of the 
blood vessels supplying the cerebral tissue.  
The focus of this thesis is patients suffering from cerebral ischaemia/infarction. 
We will now continue with a brief overview on the epidemiology of stroke. 
 
1.1 EPIDEMIOLOGY 
Stroke is one of the major causes of death and disability, being the 2nd leading 
cause of death worldwide, accounting for 6.5 million deaths (51% ischaemic 
strokes) in 2013. In 2013, the worldwide incidence in absolute numbers of first-
time stroke was 10.3 million (67% ischaemic strokes) and the global prevalence 
26 million (71% ischaemic strokes), having increased by 66% and 84% 
respectively compared to 1990 (2). Despite these increased absolute numbers, 
mortality rates have reduced in both low-, middle- and high-income countries, 
probably due to improved stroke-care (3). This increased survival has important 
implications however, as a large proportion of patients survive with long-term 
disabilities. According to 2015 data from the WHO, stroke was estimated to 
cause a total loss of 140 million Disability Adjusted Life Years (DALY´s), 
accounting for 5 % of the total number of DALY´s lost worldwide (4). The 
societal economic costs are enormous, both directly through costs for in-patient-
care, rehabilitation etc. and indirectly through loss of income. In 2010, the 
estimated cost of stroke in the EU area was estimated at a staggering 64.1 billion 
Euros (5). 
With an increasing life-expectancy, the incidence of stroke is expecting to 
increase further. One estimation is an increase in incident stroke cases from 1.1 
million to 1.5 million between 2000 and 2025 in the EU area (6).  
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The situation in Sweden is similar to the trends seen in other high-income 
countries. In 2015 close to 23000 incident cases of stroke were registered in 
RiksStroke, the Swedish national quality register for stroke care (7). During the 
same period the WHO registered a total of 7900 deaths attributable to stroke in 
Sweden (8).  Stroke incidence in Sweden has declined over the last decades, for 
ischaemic stroke reducing from 152 to 123 (per 100 000 person-years) between 
1995-2010. Mortality has declined during the same time period from 38 to 24 (per 
100 000 person-years) (9).  
This decline, seen in absolute numbers as well, has occurred in spite of an 
increasingly aging population. Notably, however, there is an increase in the 
stroke incidence among young and middle aged in Sweden (10). It is still an open 
question whether Sweden will be facing the same problems as the rest of the 
Western world, with increased costs on society due to both direct and indirect 
causes. The estimated cost of stroke, both directly and indirectly, has been 
estimated at roughly 640 000 SEK/case, with an estimated yearly cost of 18.3 
billion SEK on society (11). 
 
Figure 1A shows the overall global trend in incidence rate and mortality over the 
last two decades. Although the incidence rate overall is not increasing, and 
mortality overall has decreased, as seen in Figure 1B in absolute numbers the 
global incidence is steadily increasing. Alarmingly, an increased incidence rate 
of ischaemic stroke is seen in the younger population. The above-mentioned 
figures highlight the need for improving both primary and secondary prevention 
of stroke, as well as improving both the treatments in the acute setting and post-
stroke rehabilitation, in order to reduce the incidence of stroke and improve 
long-term outcome after incident stroke. 
 
 
 
 
  
Figure 1A. Global incidence and mortality 
rates (per 100 000 person-years) between 1995 
and 2010. 
Figure 1B. Global incidence in absolute 
numbers (millions) between 1995 and 2010. 
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1.2 CEREBRAL VASCULAR ANATOMY 
The brain is supplied by blood from four main arteries: the paired carotid and 
vertebral arteries. The gross anatomy of these originating vessels can vary, with 
several anatomical variations, however in most humans, the general anatomy is 
the following, see Figure 2 (12). 
 
 
The right common carotid artery usually arises as a branch from the 
brachiocephalic trunk, which in turn arises as a branch from the aortic arch. The 
brachiocephalic trunk also branches into the right subclavian artery. The left 
common carotid artery arises directly from the aortic arch. Both the left and 
right common carotid arteries branch into the internal and external carotid 
arteries, approximately at the level of the thyroid cartilage (C3-C5). The internal 
carotid artery (ICA) continues unbranched to the carotid canal at the base of the 
skull. This segment is called the cervical or extracranial segment. Subsequently 
it passes through the petrous segments of the temporal bone, and after giving 
off several branches terminates at the base of the brain in an anastomosis called 
the circle of Willis, see Figure 3 (13). 
The ICA branches into the middle and anterior cerebral arteries (ACA), as well 
as the posterior communicating arteries.  
The paired anterior cerebral arteries are connected through a short arterial 
segment called the anterior communicating artery. The anterior and middle 
cerebral arteries form the so called anterior cerebral circulation. The ICA 
supplies approximately 80% of the total cerebral blood flow (14). 
 
 
Figure 2.  Anatomy of the cerebral 
vasculature. From Blumenfeld, 2010 (12). 
Permission for use obtained from Sinauer. 
Figure 3. Circle of Willis. From Blumenfeld, 
2010 (12). Permission for use obtained from 
Sinauer. 
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The right and left vertebral arteries arise from each subclavian artery, and enter 
the cranial cavity at the C1 level. They anastomose and form the basilar artery at 
the pontomedullary junction. The basilar artery subsequently extends cranially 
to the terminal bifurcation and gives rise to the paired posterior cerebral arteries 
at the level of the midbrain. The posterior cerebral arteries are connected to the 
anterior circulation through the posterior communicating arteries, completing 
the full circle of Willis. Variants of the circle of Willis are common, and in one 
MR angiography study only approximately 42% of all subjects had a complete 
circle of Willis (15). 
The cerebral vascular architecture is intricate, made of several collateral backup 
systems, stepping in if acute or chronic vascular obstruction ensues. These 
consist of one principal collateral system including extracranial sources of blood 
flow and two principal intracranial collateral systems divided into a primary and 
secondary system (16), see Figure 4: 
 
1) Extracranial collaterals: this collateral system consists of anastomoses 
between the extracranial and intracranial arterial systems, for example 
several anastomoses exist between the external and internal carotid 
arteries. 
2) Intracranial collaterals, primary pathways: This primary collateral system 
consists of the circle of Willis, and provides immediate redirection of 
blood to ischaemic regions in case of obstruction to parent vessels. 
3) Intracranial collaterals, secondary pathways: Also known as 
leptomeningeal or pial collaterals (17), this system consist of a vast 
network of arterial anastomoses between distal segments of major 
cerebral arteries along the surface of the brain. This system forms a rescue 
network in case of arterial obstructions distal to the circle of Willis. The 
majority of anastomoses in the pial network connect the anterior cerebral 
circulation with the middle cerebral circulation, less between the middle 
and posterior cerebral circulations, and even more scarce between the 
anterior and posterior circulations. Anastomoses also exist between the 
vertebral and basilar arteries in the posterior circulation. 
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Figure 4. A) Extracranial arterial collateral circulation. Anastomoses from the 1) facial, 2) 
maxillary and 3) middle meningeal arteries to the ophthalmic artery and 4) dural arteriolar 
anastomoses from the middle meningeal artery and 5) occipital artery through the mastoid 
foramen and 6) parietal foramen. B, C). Intracranial arterial collateral circulation in frontal (B) 
and lateral(C) views. 1) Posterior communicating artery; 2) leptomeningeal anastomoses 
between anterior and middle cerebral arteries and 3) between posterior and middle cerebral 
arteries; 4) tectal plexus between posterior cerebral and superior cerebellar arteries; 5) 
anastomoses of distal cerebellar arteries and 6) anterior communicating artery. Reproduced 
from Liebeskind, 2003 (16). Permission for use obtained from Wolters Kluwer Health Inc. 
 
A description of the cerebrovascular anatomy would not be complete without 
mentioning some important aspects of the microscopic anatomy. The vessel-
wall architecture of systemic arterial vessels is as follows: The innermost layer, 
the tunica intima, consists of a single layer of endothelial cells, surrounded by a 
small amount of connective tissue. The intima is separated from the tunica 
media through a membrane called the internal elastic membrane. The tunica 
media is the thickest layer, consisting of mainly smooth muscle cells, elastic 
fibres and connective tissue. The media is separated from the tunica adventitia 
through a membrane called the external elastic membrane. The outermost layer 
of the systemic artery is the tunica adventitia, composed of connective tissue, 
small vessels (vasa vasorum) supplying nutrients to the vessel wall, as well as 
autonomic nerves. A picture describing the structure of the systemic artery can 
be seen in Figure 5.  
 
 
 
 
		6	
 
The vessel walls of intracranial arteries however, after passing intradurally, adopt 
a unique structure. The walls of the larger intracranial vessels have a 
substantially thinner vessel wall compared to systemic arteries with the same 
lumen width, mainly due to a substantial reduction in thickness of the 
adventitia, which is reduced by approximately five times. The tunica media is 
about half as thick as corresponding systemic arteries with the same lumen 
dimensions (13). Intracranial vessels also lack the external elastic lamina, and 
receive nutrients through gaps in the internal elastic lamina, as the vasa vasorum 
are lacking. The weaker vessel wall is compensated by both the arterial 
localization being within the protective cranial vault as well as being 
encompassed by the cerebrospinal fluid space. As the internal carotid artery 
passes through the skull-base, the diameter of intracerebral arteries gradually 
decreases in diameter. As an example, the internal diameter of the proximal part 
of the middle cerebral artery (MCA) is approximately 2.5 mm, 75% of the calibre 
of the ICA (18). The intracranial arteries gradually branch to smaller arteries and 
form the intricate network of pial vessels enclosing the brain surface as outlined 
above (16). 
Intracerebral arteries gradually decrease in size, partly due to fewer layers of 
smooth muscle cells in the tunica media. The pial arteries finally form 
penetrating arteries, which after entering the brain parenchyma form 
parenchymal arterioles. The parenchymal arterioles are nearly completely 
surrounded by astrocytic end-feet (19, 20), and deliver blood to the cerebral 
microcirculation, the neurovascular unit. 
 
 
 
 
 
 
 
Figure 5. Macroscopic structure of the 
systemic arterial vessel wall. Blausen.com 
staff; "Blausen gallery 2014". Wikiversity 
Journal of Medicine. In the public domain. 
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1.3 THE NEUROVASCULAR UNIT 
Parenchymal arterioles finally form a dense capillary network in the brain 
parenchyma. This network is the main site for oxygen and nutritional exchange. 
Cerebral capillaries are perfused with blood at all times (21), and it has been 
estimated that each neuron is supplied by its own capillary (22).The final 
destination of cerebral blood flow is the so-called neurovascular unit, see Figure 
6 (23). The neurovascular unit is a conceptualized cooperation between several 
cell-types, including endothelial cells of capillaries, basal lamina continuous 
with astrocytic end-feet, astrocytes, pericytes, neurons and other supporting 
cells. 
 
A complex and intricate dialogue takes place between the included structures, 
each cell type or structure having its specific roles, and we will here briefly 
discuss some of these unique functions. The vascular part of the unit consists of 
cerebral capillaries, the vascular wall containing a single layer of endothelial 
cells. Unlike systemic capillaries, adjacent endothelial cells are fused together 
through so called tight junctions, forming the blood-brain-barrier (BBB) and 
limiting molecular traffic to a transcellular route through the endothelial cells, 
hindering paracellular transport between the adjacent endothelial cells as is the 
case in systemic capillaries (24). The BBB facilitates the entry of selected and 
desired molecules, such as amino-acids and glucose, while excluding potentially 
harmful molecules as well as other cellular components of the blood-plasma 
such as erythrocytes and leukocytes. 
 
Figure 6. The neurovascular 
unit. From Cipollo et al, 2009 
(23).
 
Permission for use 
obtained from Nature 
Publishing Group. 
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The separating function of the BBB can be disrupted in cases of ischaemia, 
haemorrhage, inflammation, trauma and neoplasm, leading to the emancipation 
of neurotoxic products disturbing the function of the neurovascular unit (24). 
As seen in Figure 6, both pericytes and astrocytes serve important roles in the 
neurovascular unit. Pericytes share a common basement membrane with the 
endothelium, and serve a role in stabilizing the vessel, as well as releasing growth 
factors/matrix important for angiogenesis and vessel wall permeability (25). 
The role of astrocytes in the neurovascular unit include regulation of regional 
cerebral blood-flow (CBF), an involvement in ion and water homeostasis 
through the expression of water channel aquaporin 4 in astrocytic end-feet, and 
upregulation of tight-junction proteins (26). 
Finally, there is an important interplay between neurons and cerebral capillaries, 
neurons modulating CBF through neurovascular coupling, a bi-directional 
communication between neurons and the microvasculature (27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 9	
1.4 ISCHAEMIC STROKE - PATHOPHYSIOLOGY 
In this section, the basics of normal cerebral neuronal physiology will be 
outlined, followed by a description of the pathophysiology of acute ischaemic 
stroke. 
 
The adult human brain constitutes approximately 2% of the complete body 
weight (28, 29), however its high metabolic demands are clear when considering 
that it demands approximately 20% of the cardiac output in a resting state (30). 
In contrast to other organs, the brain uses glucose as its sole energy substrate, 
the glucose metabolism generating adenosine triphosphate (ATP). Among other 
uses, ATP is used for maintaining ion homeostasis across the cell-membranes as 
well as for cellular maintenance. The main role of ion homeostasis involves 
keeping Na+ and Ca2+ outside the cells and K+ inside. Average glucose 
consumption is estimated at 5.6 mg/100g/min, and average oxygen consumption 
is estimated at 3.5 ml/100g/min (31, 32).Despite alterations in systemic blood 
pressure, the cerebral blood flow needed to provide a constant flow of glucose 
and oxygen is kept relatively stable, remaining constant between mean arterial 
blood pressures of 50-150 mmHg (30). This ability is termed cerebral 
autoregulation. The cerebral blood flow is on average at a level of 50 
ml/100g/min, higher in grey matter (80 ml/100g/min) and lower in white matter 
(20 ml/100g/min) areas of the brain (33).  
 
Ischaemic stroke affects the delicate physiologic balance outlined above, and 
through a plethora of different mechanisms leads to infarcted and thereby 
irreversibly damaged brain tissue. The common denominator in all cases of acute 
ischaemic stroke is a vascular lesion causing a seized or diminished blood flow 
to downstream tissue. The mechanism of this obstruction is commonly divided 
into stroke caused by thrombosis, embolism and hypoperfusion. In this thesis, 
and especially in the third paper, we will focus on large arterial occlusion (LAO) 
which both can have thrombotic, and embolic aetiologies (and other more 
unusual aetiologies such as dissection or external compression).   
 
As outlined above, normal CBF is approximately 50 ml/100g/min. Through 
increased O2 uptake, oxygen consumption can be maintained at a level of 
3.5ml/100g/min until cerebral blood flow reaches a level of 20-25 ml/100g/min. 
Animal models have shown an association between reduction of CBF below 
these levels and reduced electroencephalographic (EEG) activity (30). In monkey 
models, the emergence of neurologic dysfunction has been seen at levels <20 
ml/100g/min (34, 35). 
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At levels below 10 ml/100g/min, cell membrane functions are affected severely 
and the time window for neuronal viability is extremely limited (36). Even 
though neurological impairment ensues directly as blood flow falls beyond 
approximately 20 ml/100g/min, irreversible tissue damage at CBF levels between 
10 and 20 ml/100g/min takes time to occur, illustrating the importance that 
duration of ischaemia has on the final fate of the brain tissue (37, 34). 
The effects of ischaemia on neurons and microvasculature will now be discussed 
separately. 
 
Already 2 minutes after seized CBF, the intracellular reserves of ATP are 
depleted. ATP drives the Na+/K+-ATPase necessary for upholding a high 
intracellular K+ concentration and a low Na+ concentration. Failure to uphold 
the membrane potential leads to depolarization, release of the excitatory 
neurotransmitter glutamate, and further depolarization (38). In the ischaemic, 
hypoxic and hypoglycemic environment, increased availability of glutamate has 
toxic effects on neurons, as well as causing cytotoxic oedema through the 
opening of cell membranes and influx of Na+ and Ca2+ together with water. 
Increased intracellular Ca2+ causes mitochondrial dysfunction (31), and through 
activation of proteolytic enzymes leads to degradation of the cytoskeleton, 
among other detrimental effects. The hypoxic environment leads to both a low-
pH environment through anaerobic metabolism and lactic acid production, as 
well as production of free oxygen-radicals which cause organelle and membrane 
lipid peroxidation (39). All these mentioned changes lead to neuronal 
dysfunction and ultimately neuronal cell death. 
 
Not only neurons are affected by ischaemia, but so too the microvasculature. 
Changes are seen here shortly after the onset of ischaemia, depending on the 
degree of cerebral blood flow reduction (40). Among the first processes that start 
involve loss of the endothelial barrier due to disruption of tight junctions. This 
leads to the exposure of tissue factor to plasma coagulation factors, leading to 
the deposition of fibrin in the vascular lumen, entangling leukocytes and 
platelets and causing a vascular obstruction. Concomitantly, leukocyte adhesion 
molecules are expressed on the endothelial surface, leading to the interaction of 
white blood cells with the endothelium, further increasing the permeability and 
disruption of the BBB (41). This early disruption of the BBB enables interactions 
between cell-types such as astrocytes and microglia with various factors in the 
plasma, leading to the release of enzymes which degrade the microvascular basal 
lamina (42). This process is seen within 1-2h of onset of ischaemia. 
All of these processes lead to an inflow of inflammatory cells into brain tissue, 
which further injures the ischaemic brain tissue (43). In addition to the cell 
necrosis caused by these processes, programmed cell death, apoptosis, is seen in 
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cells surrounding the necrotic cells. This process of apoptosis occurs even 
though the severity of reduced CBF in these areas is not sufficient to cause 
irreversible cell necrosis.  
 
In vascular occlusion and reduced downstream perfusion, CBF rates are not 
homogenous. The central parts of the vascular supply suffer the lowest blood 
flow and the worst ischaemic damage, while more peripheral parts usually have 
a better perfusion. The central areas, with blood flows 0-10 ml/100g/min 
sufficient to cause necrosis, are surrounded by areas with reduced perfusion 
between 10-20 ml/100g/min, which causes disruption of neuronal electrical 
activity, however not permanent damage to the cells. This area of still viable but 
electrically silent tissue is termed penumbra, salvageable areas of ischaemia, and 
is the target of all reperfusion treatments in acute ischaemic stroke. Figure 7 
illustrates the time-dependence of the final fate of brain tissue during a 
reduction in cerebral blood flow.  
The factors which determine the life span of the penumbra before its 
transformation into irreversibly infarcted and necrotic tissue depend on several 
factors (36):  
 
1) Collateral circulation, including both extracranial collateral circulation, 
intracranial primary and secondary collateral circulation 
2) The systemic circulation 
3) Various systemic metabolic factors 
4) Resistance of the microvasculature 
5) Dynamic changes in the vascular obstruction lesion 
 
Figure 7. Time dependence of the final fate of under-perfused cerebral tissue. Modified from 
Heiss, 2011(37). Permission for use obtained from Karger Publishers. 
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1.5 LARGE ARTERY OCCLUSION 
Obstruction of cerebral arteries (or tributary extracranial arteries) causing stroke 
can occur at any level, affecting both larger vessels such as the ICA as well as 
small penetrating arteries/arterioles such as the lenticulostriatal penetrating 
branches of the MCA. The most widely used classification of ischaemic stroke, 
the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification (44), 
separates between the main etiological subtypes of large-artery atherosclerosis, 
cardio-embolism and small-artery occlusion. In the first subtype, large-artery 
atherosclerosis, the definition of a large artery is not clearly specified, defined as 
“…stenosis or occlusion of a major brain artery or branch cortical artery, 
presumably due to atherosclerosis”. The specific arteries that are included, or not 
included, in this definition are unclear, the main point being the presumable 
atherosclerotic origin. Cardioembolism, through embolization to these major 
brain arteries or their branches, can also cause large artery occlusion. The two 
major and potential contributors of LAO are thus, using the TOAST 
classification; large-artery atherosclerosis and cardioembolism, together 
accounting for roughly 50% of all ischaemic strokes (45). Important to note 
though, the proportion of LAO forms a subset of this group. Figure 8 illustrates 
an LAO removed at necroscopy. 
 
 
The last three years, results from several randomised controlled trials have been 
published, showing the benefit of endovascular thrombectomy of LAO in acute 
 
Figure 8. Internal carotid artery with 
atherosclerotic plaque causing almost 
complete occlusion. Removed at 
necropsy. From Caplans Stroke: A 
clinical approach, 2009 (36). Permission 
for use obtained from Elsevier. 
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anterior ischaemic stroke  (46-50). In all of these trials, the benefit of acute 
endovascular treatment was shown for intracranial occlusions of the ICA 
(including T- and L-occlusions) as well as the first segment of the MCA, M1. In 
two of these studies, endovascular intervention was permitted in M2 occlusions 
as well (49, 50). Posterior circulation LAOs were not included. 
The definition of an LAO varies between studies. The classification does not 
merely serve a role for academic categorization but also bears with it 
implications on the arsenal of therapeutic possibilities. These variations in the 
definition of an LAO as well as a marked heterogeneity of study populations are 
witnessed in the large variation in the prevalence of LAO documented in the 
literature.  Across studies, prevalence ranges from 22·5–88·5% (51-58). In a large 
prospective single-centre Danish study on an unselected ischaemic stroke 
cohort admitted within 4.5h (N=637 patients), the prevalence of LAO was 
reported at 28.7% (59). In this study, 74% of single occlusions were located in 
the anterior circulation, the majority of which were situated in the middle 
cerebral artery (85%). One large US study on an unselected ischaemic stroke 
cohort (N= 578 patients) assessed within 24h found a 46% prevalence of LAO 
(53). Another study found a 54% prevalence of proximal occlusions in an 
unselected cohort of 699 acute ischaemic stroke patients (54).In the third article 
of this thesis, based on patients undergoing thrombolysis and/or thrombectomy, 
a 49% proportion of LAO was seen.  
 
In the following section, we will discuss the common arterial localisations and 
clinical presentation of large arterial occlusions in the anterior circulation, 
separately discussing occlusions/stenosis of the ICA, MCA and ACA.  
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1.5.1 Internal carotid artery 
Intrinsic lesions of the ICA can affect the entire course of the artery, the origin 
of the artery at the bifurcation of the common carotid artery is however most 
commonly affected (especially in Caucasian populations). Less commonly, the 
carotid siphon is affected, with an increased prevalence in certain ethnic groups, 
such as African-Americans (36). In disease at the bifurcation of the common 
carotid artery, the most common aetiology is atherosclerotic narrowing. 
Progressively decreasing luminal width as plaques gradually increase in volume 
increase the risk of clot formation in crevices of the plaques as well as increased 
acute thrombus formation due to plaque rupture. Therefore, lesions of this area 
can lead to symptoms of brain ischaemia either due distal embolization of 
thrombi from the vascular lesion, or due to hypo-perfusion caused by impeded  
 
blood flow through the stenosis, or in some cases due to both. Figure 9 shows 
common cerebral ischaemic patterns of patients with anterior circulation 
strokes. Ischaemic lesions following disease of the origin of the ICA usually affect 
the MCA territory, and are clinically difficult to differ from intrinsic pathology 
of the MCA (60). Motor and sensory (most often cortical sensation) deficits 
usually affect the contralateral face and arm (more than the leg), other cortical 
symptoms such as aphasia, neglect and anosognosia varying according to the 
side of the affected hemisphere. Transient Ischaemic Attacks (TIA) such as 
 
Figure 9. Common CT-locations of 
anterior circulation infarcts. (A) 
wedge-shaped MCA infarct, (B) 
entire MCA territory, (C) superior-
division MCA, (D) inferior division 
MCA, (E) ACA, (F) ACA and MCA, 
(G) striatocapsular infarct, (H) 
wedge-shaped anterior watershed 
infarct, (I) wedge- shaped posterior 
watershed infarct, (J) anterior and 
posterior watershed infarcts, (K) 
linear watershed infarct, (L) ovular 
deep watershed infarct, and (M) 
small white-matter watershed 
infarct. Reproduced from Caplans´ 
Stroke: A Clinical Approach, 2009 
(36). Permission for use obtained 
from Elsevier. 
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amaurosis fugax and transient limb paresis can precede the ischaemic stroke 
caused by ICA origin disease, by weeks or months, and are an important warning 
sign of impeding stroke. Recent data show that the 1-year risk of stroke after a 
TIA or minor stroke is approximately 5 %, lower than previously reported (61). 
Carotid siphon disease has been shown to be associated with a worse prognosis 
than origin disease, as well as with an association with coronary artery disease 
(62, 63). It commonly occurs concomitantly with extracranial ICA disease, one 
series showing tandem extracranial ICA and intracranial siphon stenosis in 62% 
of patients (62). TIAs are thought to be less common in siphon disease compared 
to extracranial ICA disease (36).  
 
1.5.2 Middle cerebral artery 
The main cause of occlusion in this arterial segment is considered to be distal 
embolism from more proximal sources: heart, aorta and extracranial carotid 
artery. However, although considered rare, intrinsic disease of the MCA may be  
 
more common than we thought. The first reports on prevalence were generated 
from mainly Caucasian populations, studies of Asian and African-American 
patients have showed a higher prevalence of intrinsic disease of the MCA (64, 
65). Common distributions of cerebral ischaemia in the MCA territory are shown 
in Figure 10. 
The symptoms of cerebral ischaemia in MCA disease can vary widely depending 
on which segments of the artery that are affected. The three main divisions of 
the MCA consist of the lenticulostriatal perforators and the superior and inferior 
divisions. An occlusion of the entire distribution of the MCA may give a total 
anterior circulation syndrome (TACI) consisting of contralateral severe 
hemiparesis, hemisensory loss, conjugate eye deviation, hemianopia and 
depending on the side of the lesion global aphasia (left hemisphere) or severe 
 
Figure 10.  
Common distributions of 
ischaemia following MCA 
occlusion. (A) normal 
cerebral hemisphere in 
coronal section, (B) occlusion 
of the upper trunk of the 
MCA, (C) occlusion of the 
lower trunk of the MCA, (D) 
infarct of the deep basal 
ganglia, (E) wedge infarct in 
the pial territory, and (F) 
whole MCA occlusion. 
Reproduced from Caplans 
Stroke: A Clinical Approach, 
2009 (36). Permission for use 
obtained from Elsevier. 
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neglect (right hemisphere). Affliction of only certain segments, either 
lenticulostriatal, upper or lower divisions, usually give a more restricted 
spectrum of symptoms. 
 
1.5.3 Anterior cerebral artery 
Pure anterior cerebral artery (ACA) infarcts are uncommon, and intrinsic 
pathology of the ACA is even rarer. The majority of ACA disease is embolic, 
originating from more proximal lesions. Different studies and registries report 
different percentages of ACA infarcts, varying from 0.5-3% (66). 
Presence of intrinsic pathology of the ACA is often associated with concomitant 
pathology of the MCA/ICA. In a report from the Lausanne Stroke Registry, only 
27 out of 1470 (1.8%) patients had isolated ACA infarcts, 17 patients with more 
proximal sources (ICA or cardiac emboli), and in only one patient was intrinsic 
ACA pathology considered the cause of infarction. The remaining ACA infarcts 
had an unknown source of emboli (67). Even though unusual, interventional 
treatment of the ACA is sometimes performed. In the MR CLEAN trial, the first 
randomised controlled trial showing a benefit of endovascular therapy in acute 
ischaemic anterior circulation stroke, A1 and A2 occlusions were included per-
protocol, and one thrombectomy was performed on an ACA occlusion (50). 
Figure 11 shows common distributions of cerebral ischaemia following ACA 
occlusion. 
The most clinically striking symptoms are usually a paralysis greatest in the 
lower extremity, especially the foot and proximal thigh, the face and hand are 
usually spared. Sometimes, in cases of extensive and large infarcts, complete 
hemiplegia is seen, the upper limb dysfunction however being secondary to 
infarction of the premotor cortex rather than the motor cortex itself. Another 
common tell-tale sign is the presence of left arm apraxia, caused by infarction of 
the corpus callosum and adjacent white matter tracts, referred to as an anterior 
disconnection syndrome. Apathy and aboulia are often seen, as well as 
incontinence. 
 
Figure 11. ACA occlusion and affected cerebral territories. Reproduced from Caplans´ Stroke: A 
Clinical Approach, 2009 (36). Permission for use obtained from Elsevier. 
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1.6 TREATMENT 
 
1.6.1 Intravenous thrombolysis 
Thrombolytic drugs have been explored for a number of different 
thromboembolic conditions since the 1950´s, using both streptokinase and 
different human and bovine thrombolysins. Small randomised trials in the 
1960´s, treating worsening ischaemic stroke patients with streptokinase within 
3 days of ictus, showed some positive effects on lysis of occlusions (68, 69). 
However, a high mortality rate and cases of intracerebral haemorrhage lead to 
serious questioning of the safety of the drug, and finally to contraindication of 
the drug also for other indications if past or present intracerebral lesions were 
present. In the 1980s studies on thrombolytic therapy in acute ischaemic stroke 
saw yet another revival, the main agents tested in these mainly observational 
studies being streptokinase, urokinase and recombinant tissue plasminogen 
activator (rtPA) (36, 70-72). In some of these studies, intra-arterial therapy was 
used, in others intravenous therapy. A common denominator in all of these 
studies was the use of angiography for identifying arterial occlusions prior to 
therapy. The intra-arterial studies combined showed a 64% recanalization, 18.5% 
haemorrhagic complication rate and 42% good outcome, whilst the intravenous 
studies showed a lower recanalization (approximately 1/3 of patients) and an 
overall higher frequency of both haemorrhagic infarct transformation and 
haematomas (70-72, 36). Three RCTs in the 1990s, testing intravenous 
streptokinase in the setting of acute ischaemic stroke, were halted due to a high 
rate of intracerebral haemorrhages in treated patients (73-75). 
 
Sparked by beneficial effects in the treatment of acute myocardial infarction with 
intravenous tissue plasminogen activator (iv-tPA), the NINDS trial investigators 
performed dose-finding studies in the early 1990s aiming at finding suitable 
dose-regimens of iv-tPA for acute ischaemic stroke (76, 77). These studies 
together with evidence from other studies on iv-tPA, both observational and 
small RCTs (78, 79), strongly suggested the need for larger RCTs evaluating the 
efficacy of iv-tPA in acute ischaemic stroke. 
 
1.6.1.1 Rationale 
Endogenous plasminogen activator is a fibrin specific serine protease produced 
by the vascular endothelium. It is part of the endogenous fibrinolytic system in 
conjunction with plasminogen, the main physiological role being limitation of 
thrombus formation and growth, as well as the maintenance of an intact 
vasculature in the setting of thrombus formation. The mode of action is the 
		18	
cleavage of inactive precursor plasminogen to active plasmin, which in turn 
effectuates local fibrinolysis through the degradation of fibrin. 
 
Recombinant tissue plasminogen activator, rtPA (alteplase), is almost identical 
to endogenous plasminogen activator. It has a high fibrin specificity, higher than 
that of streptokinase and urokinase, which results in a lower depletion of 
circulating coagulation factors (80). The half-life of unbound alteplase is 4-6 
minutes (81), however, fibrin-bound alteplase is more resilient to degradation by 
plasminogen activator inhibitor type 1, the thrombolytic effects at thrombus loci 
persisting several hours after administration (82). 
The mode of action is on the surface of the thrombus, where alteplase binds to 
fibrin strands, while other cell-receptors anchor plasminogen and plasminogen 
activator. The rate of fibrinolysis naturally also depends on the local blood flow 
and clot burden. Increasing fibrinolysis leads to gradually improved perfusion, 
and the increasingly higher throughput of alteplase by microstreaming through 
the thrombus as fibrinolysis proceeds finally leads to complete breakdown of the 
clot owing to arterial blood pulsations.  
 
Apart from pure fibrinolysis, rtPA has other effects, some physiologically 
beneficial, others potentially harmful. One of the potentially deleterious effects 
involves the activation of matrix metalloproteinases (MMPs), and more 
specifically MMP 2 and 9. In a setting where rtPA does not lead to the intended 
disruption of the clot, the simultaneous activation of these proteolytic enzymes 
can cause further ischaemic tissue damage, damaging both the neurovascular 
unit and the brain in large (83). MMPs confer these effects by degrading the 
basilar lamina surrounding the vascular endothelium (84). This leads to a 
disruption of the BBB and increases the risk of haemorrhagic transformation of 
already infarcted brain tissue, as well as brain oedema (85). Another specific 
deleterious effect accountable to tPA is its activation of platelet derived growth 
factor CC (PDGF-CC). Activated PDGF-CC stimulates PDGF receptors situated 
on astrocytic end-feet. The activation of these receptors leads to further opening 
of the BBB, increasing further neuronal and tissue damage. A randomised 
controlled pilot study at Karolinska University Hospital, studying the effects of 
a specific tyrosine kinase inhibitor, Imatinib, selectively targeting and blocking 
the PDGF-receptor in the setting of iv-tPA treated acute ischaemic stroke has 
recently been completed and showed promising results (86). This safety- and 
feasibility study confirmed the safety of this novel drug treatment in acute 
ischaemic stroke, and suggested a benefit regarding neurological outcome for 
patients treated with Imatinib. A larger confirmatory efficacy trial is in 
preparation, expected to recruit its first patient in late autumn 2017.  
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1.6.1.2 Clinical evidence 
The first large RCT was the European Cooperative Acute Stroke Study (ECASS), 
which enrolled 620 patients with acute ischaemic stroke between 1992 and 1994 
and was published in October 1995. Three hundred and thirty-three patients 
were randomised to iv-tPA administered at a dose of 1.1 mg/kg. The primary 
endpoint was the modified Rankin Scale (mRS) and Barthel index (BI) at 90 days, 
and there was no difference between the two arms in the intention to treat (ITT) 
analysis. However, the per protocol analysis (PP) showed a statistically 
significant difference in median mRS at 90 days favouring iv-tPA (87). 
Shortly thereafter, in December 1995, results from the pivotal NINDS (The 
National Institute of Neurological Disorders and Stroke) study were published 
(87). This trial consisted of two parts. The second part assessed functional 
outcome at 3 months, randomising 333 patients to either placebo or 0.9 mg/kg 
iv-tPA, a lower dose than in ECASS. Outcome at 3 months was assessed with a 
global statistic, combining 3 months BI, mRS, Glasgow outcome scale and 
NIHSS. Results were in favour of the iv-tPA group, the odds of a favourable 
outcome amounting to 1.7 (95% CI 1.2-2.6). In 1996, the US FDA approved the 
use of intravenous thrombolysis for treatment of acute ischaemic stroke within 
3h from symptom onset, followed by the publication of guidelines 
recommending the treatment (88, 89). 
 
Nearly 3 years later results from the ECASS-II, enrolling 800 patients, were 
published.  The treatment arm received rtPA at the same dose as is in NINDS. 
The study, although negative, showed a trend toward better outcome for the 
rtPA treated arm (90). 1 year later, results from the Alteplase Thrombolysis for 
Acute Non-Interventional Therapy in Ischaemic Stroke trials (ATLANTIS A and 
B) (91, 92) were published, mainly enrolling patients after the 3h time point. 
These two studies failed to show benefit of iv-tPA after the 3h time-point.  
 
Although several of these large RCTs were negative on the primary endpoint, an 
individual patient-data meta-analysis (IPD), pooling the data from the 6 
mentioned trials, showed a clear benefit of iv-tPA on favourable 3 months 
outcome (mRS<2, Barthel >94, NIHSS<2) in the 3h time-window (93). Odds for 
a favourable outcome stratified by onset to treatment time was in favour of iv-
tPA treatment: 2·8 (95%CI 1·8–4·5) for 0–90 min, 1·6 (1·1–2·2) for 91–180 min, 1·4 
(1·1–1·9) for 181–270 min, and 1·2 (0·9–1·5) for271–360 min. Figure 12 shows the 
adjusted odds ratio for a favourable outcome after iv-tPA as a function of time. 
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Symptomatic intracerebral haemorrhage (SICH) was seen in approximately 6% 
of patients, as compared to approximately 1 % in the placebo groups. In the 4.5h 
time-window, the hazard-ratio for death was not significantly different between 
the two arms. 
 
In September 2002, The European Medicines Evaluation Agency (EMEA) 
conditionally approved the use of iv-tPA in Europe for treatment of acute 
ischaemic stroke within 3h of symptom onset. The conditions were: 
 
1) Entering of all iv-tPA treated patients in an observational study for 3 
years, aiming at monitoring treatment safety. Physicians treating patients 
with iv-tPA were urged to enter patients into the observational Safe 
Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-
MOST) (94). 
2) Initiation of a new RCT, ECASS-III (95), studying the effects of iv-tPA at 
3- 4.5h after symptom onset. 
 
The SITS-MOST enrolled a total of 6483 patients from 285 centres in 14 
countries.  Results from this study were compared with the pooled results from 
the previous RCTs. A comparison of SITS-MOST and RCT data, comparing 
mortality, the proportion of patients with SICH and functional outcome at 3 
months is seen in Figure 13. 
 
 
Figure 12. Adjusted odds ratio for a favourable 3-months favourable outcome by onset-to-
treatment time (OTT). Reproduced from Hacke et al, Lancet 2004 (93). Permission for use 
obtained from Elsevier. 
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The SITS-MOST study clearly showed the safety and benefit of iv-tPA 
administered within 3 h from symptom onset in routine clinical practice, as well 
as illustrating the benefit of therapy even in non-experienced centres, a concern 
which had not been addressed previously. In summary, gathering the evidence 
from pooled randomised data and a large prospective observational registry, the 
beneficial effects of intravenous thrombolysis within 3h of symptom onset were 
very clear. 
In September 2008, the results of the ECASS-III trial and the SITS observational 
study in ischaemic stroke patients treated with IV thrombolysis in the 3-4.5h 
were published (95). The ECASS-III study enrolled patients with acute ischaemic 
stroke between 2003 and 2007 and 418 patients were randomised to the 
treatment arm. The study was positive, showing an odds ratio of 1.34 (95% CI 
1.02-1.76) in favour of the treatment group. No significant differences in 
mortality were seen between treatment and placebo arms, however in line with 
previous results, rates of SICH per ECASS-III definition differed between the 
groups, 2.4% in the treatment arm vs. 0.2% in the placebo group; P = 0.008. 
Similar results were seen in a SITS publication from the same year, comparing 
the 0-3h treatment window with the 3-4.5h window. No significant differences 
in mortality, SICH or functional outcome were seen between the two treatment 
time windows. 
 
The results of ECASS-III and the SITS publication led to a widening of the 
European and US guidelines, now including the 3-4.5 h time-window as a 
possible treatment frame (96, 97). These guidelines were further strengthened 
by a pooled meta-analysis published in 2010, including ECASS-III, and 
confirming the beneficial effects of iv tPA up-to 270 minutes (98). 
Based on this study, Table 1 shows the Number Needed to Treat (NNT) by 
increasing onset-to-treatment time.  
 
 
 
 
Figure 13. Results from the SITS-MOST study. Reproduced from Wahlgren et al, Lancet 2007 
(94). Permission for use obtained from Elsevier. 
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Treatment delay Number needed to treat (NNT) 
0-90 min 4.5 
91-180 min 9 
181-270 min 14.1 
Table 1. The Number Needed to Treat (NNT) with iv-tPA for gaining one additional patient with 
an excellent functional outcome (mRS 0-1) (98). 
 
Despite changes in guidelines regarding the extended time-window for iv-tPA 
treatment, questions still remained to be answered. Doubts had been lingering 
for a long time regarding the efficacy and safety of treatment in elderly patients, 
as well as in patients suffering from both very mild as well as very severe strokes. 
Observational data from SITS published in 2010 had already indicated the safety 
and beneficial effects of iv-tPA irrespective of age, however no RCT had yet 
proven the efficacy and safety of iv-tPA in the elderly (99, 100). 
The 3rd International Stroke Trial (IST-3) sought to shed light on these and other 
issues (101). The results of this study were published in June 2012. The trial 
enrolled a total of 3035 patients from 12 different countries, 1515 patients 
randomised to iv-tPA (dose 0.9mg/kg) and the rest to placebo. 53% of patients 
were older than 80. The trial was negative at the primary endpoint of functional 
status (measured as a dichotomy on the Oxford Handicap Score). On a pre-
specified secondary analysis examining a shift on the same scale however, a 
common odds ratio of 1.27 (95% CI 1.10-1.47) in favour of treatment was seen. In 
another pre-defined subset analysis, a trend toward better efficacy was seen in 
elderly patients, and trends were also seen toward increased benefit in more 
severe strokes.  
 
Following IST-3, two large meta-analyses, one pooled data and one Individual 
Patient Data (IPD) meta-analysis, have been published (102, 103). 
The first pooled meta-analysis was published just one month after the 
publication of IST-3, and included a total of 12 trials and 7012 patients (103). A 
clear benefit of iv-tPA administered within 3h regarding functional 
independency (mRS 0-2) at final follow-up was seen (OR 1·53, 95% CI 1·26–1·86, 
p<0·0001). An increased mortality within 7 days was seen in the treated arm. This 
was however offset by a subsequent lower mortality, resulting in no significant 
differences at final follow-up. No statistically significant differences in functional 
outcome at final follow-up in the patients randomised to treatment in the 3-6h 
time-window were seen. 
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The largest IPD meta-analysis, based on data from thrombolysis RCTs, was 
published in 2014, including a total of 6756 patients from 9 different trials (102). 
It finally answered several questions previously lacking clear answers, such as 
the effect of thrombolysis in the elderly and in patients with very mild or severe 
strokes. Overall an OR of 1.75 (95% CI 1.35–2.27) favouring iv-tPA for a good 3-6 
month functional outcome (mRS 0-1) in the 0-3h time-window was seen. In the 
3-4.5 h time-window the odds ratio was 1.26 (95% CI 1.05–1.51) and in the time-
window >4.5h the odds ratio was 1.15 (95% CI 0.95-1.40). Alteplase, as shown in 
all previous trials, significantly increased the risk of intracranial haemorrhage, 
however the relative increase in risk was similar irrespective of age, stroke 
severity or treatment delay. Important to note though, the absolute increase in 
risk in iv-tPA-treated patients was higher for patients who had more severe 
strokes. The results are summarized in Figure 14. 
 
 
Emberson et al´s meta-analysis is the most extensive and clarifying summary of 
the available evidence on intravenous thrombolysis in acute ischaemic stroke. 
Finally, before concluding this section on the clinical evidence of iv-tPA in acute 
ischaemic stroke, one recent study needs to be mentioned. The ENCHANTED 
trial, published in June 2016, sought to investigate the efficacy and non-
inferiority of a lower dose alteplase, 0.6 mg/kg, compared to the standard dose 
of 0.9 mg/kg (104). The main rationale was investigating whether a low dose was 
as effective at improving recovery, but possibly with a lower incidence of 
intracerebral haemorrhage. A total of 3310 patients were enrolled and 
 
Figure 14. Main results from the largest IPD (Individual Patient Data) meta-analysis for iv-tPA 
in acute ischaemic stroke, presenting the proportion of patients with a good functional outcome 
(mRS 0-1). * Each subgroup after adjustment for the other two baseline characteristics. 
Reproduced from Emberson et al, Lancet 2014 (102). Permission for use obtained from Elsevier. 
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randomised to either low-dose or standard-dose alteplase. The study was 
negative and non-inferiority not proven (OR for poor functional outcome 1.09, 
95% CI 0.95-1.25, P=0.51 for non-inferiority). However, in a secondary outcome 
analysis assessing a shift on the Rankin scale, non-inferiority was shown. 
Significantly less intracerebral haemorrhage was seen in the low-dose group 
compared to standard-dose. For the time being, standard-dose alteplase has 
remained the mainstay treatment. Nonetheless, future RCTs might shed light on 
the clinical situation in which, due to a concern over SICH, selected patients may 
be chosen for a low-dose approach. 
 
1.6.2  Endovascular thrombectomy 
Iv-tPA for acute ischaemic stroke has been an approved treatment for close to 15 
years in Europe, and even longer so in North America. However, the efficacy of 
iv-tPA in patients with increasingly larger thrombotic burden varies. Previous 
studies have shown decreasing rates of recanalization following iv-tPA 
treatment the more proximal the occlusion site. One retrospective study of 335 
iv-tPA treated patients monitored using bed-side transcranial Doppler showed a 
decreasing rate of 2h post thrombolysis recanalization the more proximal the 
site of occlusion (105). Recanalization was seen in: 44% of distal MCA occlusions, 
30% of proximal MCA occlusions, 27% of tandem ICA/MCA occlusions and in 
only 6% of terminal ICA occlusions. Similar results were seen in earlier pre-
NINDS iv-tPA dose-escalation studies (106). In an observational study of 138 iv-
tPA- treated patients, thrombus length, measured as length of hyper-intensity 
on non-contrast enhanced CT scans (hyper-dense middle cerebral artery sign), 
was correlated with recanalization status post-thrombolysis. No patients with 
clot lengths 8 mm or above recanalized after iv-tPA(107). These and other 
findings suggested the need for other revascularization therapies in acute 
ischaemic stroke. 
 
1.6.2.1 Clinical evidence 
Early attempts at endovascular treatment of acute ischaemic stroke caused by 
identifiable vessel occlusions can be found from the early 1980s. These first 
studies examined recanalization rates and efficacy of intra-arterial thrombolysis. 
Two cases series(108, 4) and one retrospective cohort study(109) reported 
positive results of this approach as compared to best medical treatment at the 
time of the studies. This led to the first randomised attempts at investigating the 
efficacy of intra-arterial (ia) thrombolysis in acute ischaemic stroke with 
confirmed vessel occlusion: PROACT I and PROACT II (both published in the 
late 90s) (110, 111). Both studies showed higher recanalization in the patients 
treated with ia thrombolysis compared to placebo (PROACT I: 57 vs. 14 %) or 
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heparin alone (PROACT II: 66% vs 18%). PROACT II showed a significantly 
higher rate of 90-day functional independence as measured by mRS 0-2 (40% vs 
25%). Despite these positive results, the therapy was not approved by the US 
FDA. Following PROACT I and II, in late 1999 the results from the Emergency 
Management of Stroke Trial (EMS) were published (112). This small pilot trial 
showed a better recanalization rate in patients treated with combined ia and iv 
thrombolysis compared to ia thrombolysis alone. EMS was followed by the larger 
Interventional Management of Stroke Study (IMS-I), a study comparing patients 
treated with a combined ia and iv thrombolysis approach with historical controls 
from the NINDS study (both placebo and iv-tPA treated). This study showed a 
non-significant lower mortality in the iv and ia thrombolysis as compared to iv-
tPA alone and encouraged a future RCT comparing the two approaches. IMS-I 
was followed by IMS-II, an extension cohort study with a similar design, showing 
a significantly better functional outcome comparing combined ia and iv-tPA 
with both sole iv-tPA-treatment as well as placebo controls from the NINDS 
study (113).  
 
During this time period, in which the ia thrombolysis approach was subject to 
investigation, several innovations and developments were seen in the technical 
field of interventional neuroradiology. New techniques and methods were being 
developed and tested. The first device for neurovascular thrombectomy to gain 
approval was the MERCI coil retriever in 2005, see Figure 15.  
 
 
The principle was clot retrieval through a corkscrew shaped coil for engagement 
and retrieval of a thrombotic occlusion. The device showed a favourable 
recanalization rate of 64% in patients treated with concomitant ia-tPA infusion 
(114).  
  
Figure 15. Merci retriever system to the left and stent-retriever to the right. Picture to the left 
from Wikipedia.org, in the public domain. Picture to the right with permission from Medtronic. 
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The second device gaining approval was the Penumbra system, thrombectomy 
performed either through direct aspiration or by clot fragmentation followed by 
aspiration (115). In a prospective, multicentre single-arm study, a total of 125 
patients were treated with the Penumbra system within 8h from symptom onset. 
82% of patients recanalized post-treatment. The latest devices entering the 
market were the so-called stent retrievers, of which Solitaire and Trevo were 
among the first. These stent retrievers had advantages over older devices, 
including better engagement with the occlusion as well as immediate restoration 
of blood-flow even before the thrombus was removed. The superiority of both 
devices over the older MERCI were shown in two randomised clinical trials, 
Solitaire with Intention For Thrombectomy (SWIFT) and Trevo versus MERCI 
retrievers for thrombectomy revascularization of large-vessel occlusions in acute 
ischaemic stroke (TREVO-2) (116, 117). Higher rates of revascularization (89 vs. 
67 % in SWIFT and 86% vs. 60% in TREVO-2) and improved functional outcome 
(36% vs. 29 % functional independence in SWIFT comparing Solitaire with 
MERCI and 40% vs. 22 % in TREVO-2 comparing TREVO with MERCI) were 
seen. 
These results were published in 2012. 
 
Thus, major developments were seen in the field of interventional 
neuroradiology in the first decade of the 21st century. However, enrolment of 
patients is a time-consuming process, and the first three randomised trials 
comparing endovascular therapy with best medical management/iv tPA were 
published jointly in 2013, IMS-III, SYNTHESIS and MR RESCUE (118-120). These 
three trials took between 5-7 years to complete. To the dismay of the stroke 
physician community, all three trials were negative, and did not show any 
benefit of endovascular therapy over standard medical treatment. Seemingly, the 
therapeutic options available in the acute management of stroke were back to 
square one. However, important and serious drawbacks in the design of these 
studies soon became evident. In IMS-III, approximately 20% of patients 
randomised to the interventional arm were subsequently not treated due to 
lacking a large vessel occlusion. Time from symptom onset to endovascular 
treatment was also long, probably reducing the experienced benefit in the 
endovascular arm, and finally less than 5% of the patients were treated with the 
newer stent-retrievers, previously shown to be clearly superior to the older 
devices. In SYNTHESIS, documentation of a large vessel occlusion prior to 
randomisation was not mandatory, and 60 % of the patients randomised to the 
endovascular arm were treated with IA thrombolysis, only 13% with modern 
stent-retrievers. In MR RESCUE, no patients were treated with modern stent 
retrievers. A sub-analysis of IMS-III, only including patients with documented 
large vessel occlusion, showed a statistically significant benefit of endovascular 
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treatment over standard therapy. Importantly, all these three trials proved the 
safety of interventional treatment, as intracerebral haemorrhages and other 
serious adverse events did not differ between the treatment arms. The need for 
new trials comparing endovascular treatment using modern stent-retrievers 
with standard care including iv-tPA in patients with verified arterial occlusions 
were much needed. 
 
Finally, in late 2014 and early 2015, the long-awaited break-through finally came. 
In December 2014, results from the first RCT comparing modern stent-retrievers 
with standard care including intravenous thrombolysis, the Multicentre 
Randomized Clinical Trial of Endovascular Treatment for Acute Ischaemic 
Stroke in the Netherlands, MR CLEAN, were published (50). The trial enrolled a 
total of 500 acute ischaemic stroke patients with occlusions in the anterior 
circulation, 233 patients randomised to intra-arterial treatment (or both iv-tPA 
and intra-arterial intervention) within 6h of symptom onset, the control group 
receiving standard care including iv-tPA. Of the patients randomised to the 
endovascular arm, retrievable stents were used in 82% of patients. The trial 
showed a clear benefit of endovascular treatment, a common adjusted odds ratio 
of 1.67 (95% CI 1.21-2.30) for a favourable shift in the 90 days modified Rankin 
Scale, in favour of the endovascular arm. No significant differences in mortality 
or SICH were seen.  
 
This breakthrough was followed by four other randomised clinical trials, all 
published in The New England Journal of Medicine early 2015. These were: The 
Endovascular Treatment for Small Core and Anterior Circulation Proximal 
Occlusion with Emphasis on Minimizing CT to Recanalization Times (ESCAPE)  
(48), Extending the Time for Thrombolysis in Emergency Neurological 
Deficits—Intra-Arterial (EXTEND-IA) (49), Randomized Trial of 
Revascularization with Solitaire FR Device Versus Best Medical Therapy in the 
Treatment of Acute Stroke due to Anterior Circulation Large Vessel Occlusion 
Presenting Within 8 h of Symptom Onset (REVASCAT) (47) and Solitaire With 
The Intention for Thrombectomy as Primary Endovascular Treatment for Acute 
Ischemic Stroke (SWIFT PRIME) (46). These 4 subsequent trials were stopped 
after interim analysis crossed pre-specified boundaries of efficacy. In 2016, final 
results from two additional trials, Mechanical thrombectomy after intravenous 
alteplase versus alteplase alone after stroke (THRACE): a randomised controlled 
trial (121) and the Randomized Concurrent Controlled Trial to Assess the 
Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke, 
THERAPY (122), were published. 
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In summary, all of these studies but one, THERAPY, showed clear statistically 
significant beneficial effects on long-term functional outcome in patients with 
documented large vessel occlusion treated with mechanical thrombectomy. 
THERAPY was halted prematurely after the publication of the previous positive 
studies and was thus underpowered to show the intended treatment effect, 
although the direction of effect was similar as in the other trials. In addition, 
THERAPY was the only trial using the Penumbra system instead of modern 
stent-retrievers. 
 
Safety regarding mortality and intracerebral haemorrhage was consistent. The 
effect size, measured by the number needed to treat (NNT) varied in an 
impressive range of 3.2-7.1 (123). The trials did vary in inclusion criteria, in the 
intervention used as well as in the therapeutic time window, a summary of the 
main study details and results can be seen in Figure 16 (123). All trials except 
THERAPY used mainly modern stent retrievers. Age-limitations were applied in 
REVASCAT, THERAPY, SWIFT-PRIME and THRACE, whereas EXTEND-IA, MR 
CLEAN and ESCAPE had no age-limits. In all trials, CT/MR angiography was 
performed pre-randomisation to determine the mandatory presence of a large 
vessel occlusion for trial enrolment. Only patients with occlusions in the anterior 
circulation were included, and in most studies the site of vessel occlusion was 
limited to the terminal internal carotid and M1 segment of the middle cerebral 
artery. MR CLEAN (50) and EXTEND-IA (49) were the only studies also 
including more distal M2 occlusions.  
		 29	
 
 
Fi
gu
re
 16
. S
um
m
ar
y 
of
 s
tu
dy
 c
ha
ra
ct
er
is
tic
s 
an
d 
re
su
lts
 fr
om
 th
e 
m
aj
or
 ra
nd
om
is
ed
 c
on
tr
ol
le
d 
tr
ia
ls
 o
n 
en
do
va
sc
ul
ar
 in
te
rv
en
ti
on
 in
 a
cu
te
 is
ch
ae
m
ic
 s
tr
ok
e.
 R
ep
ro
du
ce
d 
fr
om
 C
am
pb
el
l 
et
 a
l, 
La
nc
et
 2
01
5 
(1
23
). 
Pe
rm
is
si
on
s 
ob
ta
in
ed
 fr
om
 E
ls
ev
ie
r.
 
		30	
The majority of studies recruited patients within the 0-6h time-limit, and the 
beneficial effects of endovascular therapy after this time-limit are therefore 
lacking. The ESCAPE trial did include 49 patients treated within the 6-12 h time-
period and showed trends toward benefit even in this late time-period (OR 1.7 in 
favour of the endovascular arm), however the results did not reach the 0.05 
significance level. In SWIFT-PRIME (46) and EXTEND-IA (49), more rigorous 
selection criteria were employed, advanced techniques assessing collateral status 
and perfusion imaging in selection of patients probably resulting in the observed 
higher recanalization rates and higher proportion of beneficial functional 
outcome in these studies. These two trials and ESCAPE (48) also emphasized the 
importance of minimizing time from symptom onset to endovascular treatment, 
and are the three trials showing the highest probability of functional 
independence (OR 2.73-3.75) and revascularization (72 to 89 %). 
 
Most of the studies were stopped prematurely after the release of the MR CLEAN 
results, and therefore were underpowered to answer specific questions regarding 
the beneficial effects in certain subgroups. After the publication of these five 
main studies, several meta-analyses publications have appeared in the literature 
(124-128). However, the most powerful and efficient way of addressing questions 
that have not been previously resolved in individual trials is pooled data analyses 
in IPD meta-analysis, thereby adjusting for various prognostic factors at the 
individual patient level. The most recent pooled patient-level meta-analysis of 
the recent thrombectomy trials was published in The Lancet in April 2016 (129). 
This meta-analysis managed to answer several questions still remaining after the 
individual trials were published. The main results can be seen in Figure 17. 
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The main message from this analysis is the following: 
 
1) The number needed to treat (NNT) with thrombectomy to reduce the 
functional disability by one level on the mRS scale is an impressive 2.6 
2) Effect sizes favouring thrombectomy were seen across several subgroups, 
including: Patients >80 years of age, patients not receiving alteplase, 
patients treated after 300 minutes. 
3) In patients with low NIHSS scores, trends toward a good functional 
outcome favouring the endovascular group were seen, however not 
reaching statistical significance. 
 
Some questions still remain open. The trials so far included only patients with 
occlusions in the anterior circulation. Studies are underway investigating the 
beneficial effects of thrombectomy in the posterior circulation (130). Other 
studies investigating treatment in a later time-window, 6-24h, are ongoing 
(DAWN- Trevo and Medical Management Versus Medical Management Alone 
in Wake Up and Late Presenting Strokes; ClinicalTrials.gov 
NCT02142283 and POSITIVE- Perfusion Imaging Selection of Ischaemic Stroke 
Patients for Endovascular Therapy; ClinicalTrials.gov NCT01852201). 
 
 
 
Figure 17. Adjusted treatment effects for mRS at 90 days. cOR=common odds ratio. Subgroup 
outcomes from individual patient-data meta-analysis of the major randomised controlled trials 
on mechanical thrombectomy in acute ischaemic stroke (129). Reproduced from Goyal et al, 
Lancet 2016. Permission for use obtained from Elsevier. 
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1.7 FUNCTIONAL OUTCOME 
 
1.7.1 Assessing outcome after stroke 
Stroke is an acute condition, causing immediate symptoms of neurological 
dysfunction at the time of disease onset. The aftermath however, in case the 
patient survives, is often a life-long debilitating condition with multilevel effects. 
Due to these multilevel effects, outcome after stroke can be difficult to describe 
without overlooking important aspects significant to the patient´s overall 
recovery. 
 
The only way of assessing treatment effects is by measuring changes in outcome 
parameters. Investigating treatment effects on parameters such as hypertension 
or hyperlipidemia are straightforward, while the multilevel effects of stroke 
complicate outcome assessment. In order to conceptualize the 
multidimensional effects of a chronic disease, the World Health Organization 
(WHO) has stipulated the WHO International Classification of Functioning, 
Disability and Health (WHO-ICF), a framework aiding and structuring the 
description of a chronic disease such as stroke (131). In this framework, the effects 
of a chronic disease are separated into pathology (e.g. the stroke lesion), 
impairment (e.g. hemianopia), limitations in activity (e.g. cessation of driving 
due to a visual disturbance) and societal participation (e.g. social isolation due 
to difficulties leaving the home). Figure 18 depicts this concept, illustrating the 
feed-back loops that often ensue. 
 
 
Figure 18. The World Health Organization International Classification of Functioning, 
Disability and Health (WHO-ICF) framework. Reproduced from Harrison et al, 2013 (132). 
Permission not required. 
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The individual elements of the WHO-ICF are conceptually separate, however 
there may be significant overlap, and the underlying relationships between the 
different elements are not fully understood (133). No single scale or score can 
assess the outcome at all different levels of the WHO-ICF, a review article from 
2009 found 47 different stroke outcome scales currently used in clinical trials 
(134).  
 
Various scales focus at different levels, and which level to focus on is not obvious. 
Deficits at the level of impairment, such as neurological deficits after a stroke, 
are relatively easy to measure, are clearly correlated with site and the mass of 
damaged cerebral tissue and therefore measurements at this level probably 
reflect the pathophysiology that the trial drugs/interventions purport to affect. 
However, patients are probably more interested in their level of activity, which 
is described in the third level of the WHO-ICF framework. Further, the effects 
on future societal participation are naturally highly prioritized by the stroke 
patients. Assessing outcome after stroke in a meaningful way, both in trials but 
also in routine clinical practice, is clearly not a simple task. Furthermore, apart 
from the choice of level to focus on, the chosen score needs to be both valid, i.e. 
truly measure the concept meant to be measured, reliable, i.e. show consistency 
in scoring between assessors (inter-rater-reliability) and reproducible in repeat 
scoring by the same assessor (intra-observer-reliability). A common measure of 
inter-rater variability is the kappa score, ranging 0-1 (135). Following standard 
convention, a kappa between 0-0.2 is usually considered poor, 0.21-0.4 fair, 0.41-
0.6 moderate, 0.61-0.8 good, and 0.81-1.00 excellent (136). In addition, the scale 
needs to be responsive i.e. in a satisfactory way measure change over time. 
Finally, it needs to be acceptable to both assessor and patient (132). The demands 
on an outcome scale are extensive.  
In a systematic review of the outcome measures used in all published RCTs on 
drug intervention in acute stroke, reviewing close to 60000 patients, the 
distribution of outcome level studied as the primary endpoint were the 
following: 20 studies used a measure of activity limitation as the primary 
outcome, 7 studies used some measure of level of impairment, and no study used 
a measure of participation (137). A more recent review from 2009 examined 
outcome assessment in recent stroke trials from major high-impact journals 
(134). The three most common outcome assessments described were the 
following: the mRS (64.3%); followed by Barthel index (40.5%) and the NIHSS 
(27.8%) (134). The mRS is a global outcome assessment, incorporating elements 
from both level of impairment, activity and participation. The Barthel Index is a 
measure of activity while the NIHSS is an impairment measure. These three 
major outcome scores will now be reviewed in more detail, with emphasis on the 
mRS which is the focus of the last project in this thesis (138). 
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1.7.1.1 The National Institute of Health Stroke Scale 
The National Institute of Health Stroke Scale, NIHSS, is a 15-item ordinal non-
linear measure of neurological deficits, mainly assessing symptoms associated 
with acute anterior circulation stroke. The score covers symptoms of 
consciousness, motor function, sensory function, coordination, neglect, 
language, visual fields and extraocular movements (139). 
The scale ranges from 0-42, increasing scores representing increasingly severe 
stroke. Table 2 summarizes the included items.                                                                                                      
Table 2. National Institute of Health Stroke Scale. Image created by the author of this thesis. 
 
NIHSS sub-item Results Scoring 
Level of consciousness Alert 0 
Not alert (arousable to minor stimulation) 1 
Not alert (arousable to painful stimulation) 2 
Unresponsive 3 
Level of consciousness Questions Answers both correctly 0 
Answers one correctly 1 
Answers neither correctly 2 
Level of consciousness Commands Performs both tasks correctly 0 
Performs one task correctly 1 
Performs neither correctly 2 
Best gaze Normal 0 
Partial gaze palsy 1 
Forced deviation 2 
Visual No visual loss 0 
Partial hemianopia 1 
Complete hemianopia 2 
Bilateral hemianopia 3 
Facial palsy Normal 0 
Partial central paralysis 1 
Complete central paralysis 2 
Peripheral or bilateral paralysis 3 
Motor function (arm) 
a) Left 
b) Right 
No drift within 10 seconds 0 
Drift within 10 seconds, does not reach bed 1 
Drift within 10 seconds, reaches bed. 2 
No effort against gravity 3 
No movement 4 
Motor function (leg) 
a) Left 
b) Right 
No drift within 5 seconds 0 
Drift within 5 seconds, does not reach bed 1 
Drift within 5 seconds, reaches bed. 2 
No effort against gravity 3 
No movement 4 
Limb ataxia No ataxia 0 
Ataxia in one limb 1 
Ataxia in two limbs 2 
Sensory No sensory loss 0 
Mild sensory loss 1 
Severe sensory loss 2 
Language Normal 0 
Mild aphasia 1 
Severe aphasia 2 
Mute or global aphasia 3 
Dysarthria Normal 0 
Mild to moderate dysarthria 1 
Severe dysarthria 2 
Extinction and inattention Absent 0 
Mild (1 sensory modality) 1 
Severe (2 modalities) 2 
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In patients with a reduced level of consciousness, all elements are not assessable, 
and rules are available for scoring in these situations. The score was initially 
developed in the 1980s as a measure of neurological deficits in acute-stroke trials, 
incorporating elements from several earlier scores, and was further refined in an 
acute stroke trial of naloxone (140). Since then, the usage has spread from a 
neurological impairment assessment in stroke trials to use in clinical routine 
acute-stroke practice as well. Several important trials on treatment in acute 
stroke have used the NIHSS as either primary or secondary endpoint. 
As discussed above, an outcome scale needs to have both a high validity, 
reliability, responsiveness and ease of use. Regarding validity, the NIHSS has 
shown both high content, concurrent and predictive validity. Content validity, 
assessing the internal structure of the NIHSS and correlations with clinical 
stroke-related neurological deficits has been shown (141). Concurrent validity 
has been shown in several studies with clear correlations between NIHSS scoring 
and volume of infarct (142, 143). Predictive validity, assessing associations 
between NIHSS scoring and long-term outcome has also been demonstrated 
(144, 145).  
 
Regarding reliability, high both inter-rater and intra-rater reliability has been 
shown, both in neurologist as well as non-neurologist assessors (146, 147) as well 
as in remote assessment by telemedicine (148). The score is often used in trials 
and clinical routine for assessing changes in neurologic deficits over time using 
serial NIHSS assessments, and a change in 2 points over time has been 
considered a fair approximation of either clinical deterioration or improvement 
(145). The score is fairly simple and can be completed within 6 minutes. 
Certain drawbacks need to be addressed though. Certain elements of the score 
(facial motor function, dysarthria, level of consciousness and ataxia in particular) 
have either shown redundancy or poor reliability (149). Differences in median 
NIHSS scores of equal sized infarcts of left vs right cerebral localization have 
been demonstrated, probably due to the NIHSS including 7 points correlated to 
language function, but only 2 points to neglect (150). Additionally, the score is 
poor at recognizing and grading deficits from the posterior circulation. 
In summary, the NIHSS is a wide-spread scoring model, used in both clinical and 
trial settings, with an overall good reliability, validity, responsiveness and ease 
of use. However, certain drawbacks and limitations of use need to be kept in 
mind. 
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1.7.1.2 The Barthel Index 
The second measure of outcome after stroke that will be reviewed is the Barthel 
Index (BI). The BI was developed in the mid 60´s and according to a review from 
2009 is the second most commonly used assessment tool in clinical stroke trials 
(134). The score assesses outcome at the level of activity. The BI assesses 10 
different functional tasks (activities of daily living), the score ranging from 0 to 
100. Lower scores indicate higher levels of dependency, while higher scores are 
associated with higher levels of independency. Figure 19 summarizes the 
included elements and scoring. 
 
Earlier systematic reviews suggested that the BI was the most commonly used 
endpoint in acute stroke studies, however in more recent meta-analysis the score 
has fallen down to a second place (137, 134). The scale has shown promising inter-
rater and intra-rater variability  (151, 152). This has also been confirmed in studies 
assessing reliability of the BI administered over telephone as well as in proxy’s vs 
patients (153). The scale has shown a good validity for forecasting recovery, 
required care level and duration of rehabilitation post-stroke (154, 155). 
Moderate correlations between the score and infarct volumes have been shown, 
i.e. concurrent validity (143).  
 
However, important drawbacks limit its use. These include the lack of the 
endpoint death complicating analysis in stroke trials, as well as problems with 
“floor and ceiling” effects (156).  The original intended use of the scale was a 
measure of responsiveness, assessing improvements in recovery over time in 
order to assist in discharge planning. This parameter is however the most 
important limitation of the scale. Floor and ceiling effects describe the 
insensitivity of the score in differentiating between levels of functioning at the 
two ends of the scale. For instance, patients may score 100 points, suggesting a 
completely independent level of functioning, however deficits such as language 
dysfunction which are not included in the assessment would in practice mean 
 
Figure 19. The Barthel Index. Reproduced from Harrison et al, 2013(132). Permission not 
required. 
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full-time assistance when the patient is outside his/her home. On the lower end 
of the scale, important recoveries in a severely affected patient in the 
rehabilitation setting may not be reflected by a change in BI scoring. 
Optimally, instead of only assessing the total BI score, assessment of the 
individual items would give the best overall picture of the patients´ needs. 
However, in a trial setting, dichotomizations of the total score are often 
performed, and controversy exists as to the most optimum definition of good 
outcome vs poor outcome according to the BI. Different cut-points have been 
employed in different studies, complicating comparisons between studies as well 
as proper meta-analysis (157). 
In summary, the BI demonstrates several advantages, showing both a high 
validity and reliability. However, important floor-and-ceiling” effects limit its 
use, and it has increasingly been replaced by the modified Rankin Scale. 
 
1.7.1.3 The modified Rankin Scale 
John Rankin published the original Rankin Scale in the Scottish Medical Journal 
in 1957  (158). The scale was originally intended for assessment of stroke patients 
in his prototypic stroke-unit in Glasgow, Scotland. The scale was subsequently 
modified slightly in 1988 in the UK TIA-aspirin trial in order to improve its 
comprehensiveness (the main modification involving the addition of the 
previously not included grade 0, as well as minor changes in the wording for 
minimizing ambiguity : the mRS was born (159). 
The mRS is a 6-item ordinal and hierarchical scale, ranging from 0 (no residual 
symptoms) to 5 (indicating very severe disability). In clinical trials, an additional 
score of 6 is usually added, denoting death. Figure 20 summarizes the levels of 
the mRS. The scale is today the most commonly used primary/secondary 
endpoint in clinical stroke trials (134) and is used in routine clinical follow-up 
assessments after acute stroke.    
  
 
 
Figure 20. Modified 
Rankin Scale. Reproduced 
from Harrison et al, 2013 
(132). Permission not 
required. 
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Numerous studies have ascertained the validity of the mRS (160). In summary, 
the mRS score has shown both clear correlations between increasing stroke 
severity and higher mRS scores in the long-term. In one study, the specific 
association between baseline stroke severity, measured with the NIHSS, and 
favourable outcome (mRS 0-1) was measured, showing that patients with mild 
strokes (NIHSS 1-5) had a higher chance of achieving a favourable outcome 
compared to more severe strokes (NIHSS  11-15, 16-20 and >20) (161). Several 
studies have shown clear associations between increasing stroke lesion volume, 
measured through Magnetic Resonance Diffusion Weighted Imaging (MR-DWI) 
among other techniques, and higher mRS grades (162, 163). Comparisons 
between the mRS and other outcome scales have shown good agreement, 
especially with the Glasgow Outcome Scale (GOS) (164). 
 
Regarding responsiveness of the score, being able to detect changes over time, 
limited evidence is available (160). Comparisons with the BI have shown a better 
ability of the mRS in detecting changes in mild-moderate disability (165). The 
mRS is poor at detecting short-term changes as each category encompasses a 
broad range of clinical phenotypes, whereby smaller short-term changes may not 
be sufficient for a transition of grading. 
 
Due to several reports on a high rate of inter-rater variability for the mRS, the 
clinometric property of reliability has received most attention. Intra-rater 
reliability has generally been encouraging (166), however less so for inter-rater 
reliability. A meta-analysis covering 10 studies and close to 600 patients 
investigating the reliability of the scale, demonstrated an overall un-weighed 
kappa of 0.46 (166), defined as only moderate agreement according to existing 
conventions (136). Another study investigating the agreement across multiple 
raters displayed an unweighted kappa of 0.25 (167). Various methods for 
increasing the inter-rater-agreement of the mRS have been proposed, including 
the use of a structured interview (168, 167), use of digital training resources (169) 
as well as remote consensus grading by experienced trialists. The benefits of the 
structured interview have been varying, the initial publications assessing the 
new method showing improvement (weighted kappa 0.91 vs 0.71), however 
subsequent validations in independent groups failing to show significant 
improvement (unweighted kappa 0.5 vs 0.64, no significant difference at the 0.05 
p-level)  (167, 170).  
 
One specific form of the structured interview that needs mention is the Rankin 
Focused Assessment (RFA) (171), as it forms the base for the last study in this 
thesis. The RFA was developed by Jeffrey Saver and colleagues and published in 
2010. It is a modified version of the structured interview proposed by Wilson et 
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al (168). The main differences compared to the previously proposed structured 
interview is the encouragement of eliciting outcome information from multiple 
sources, as well as rating current functional status without the need for factoring 
out pre-stroke disability, a factor complicating the assessment in the previous 
structured interview. In the original article, an extremely impressive weighted 
kappa of 0.99 and unweighted kappa of 0.93 was seen. To our knowledge, no 
external validations of the RFA have subsequently been performed.  
 
Comparisons between studies are difficult to interpret due to a high level of 
heterogeneity in the specific manner in which the endpoint mRS is analysed: 
either various dichotomizations spanning the entire range of the scale or overall 
shifts. To complicate matters even more, there is no clear consensus regarding 
the statistical method for assessing inter-rater variability. Inter-rater variability 
is usually assessed using kappa statistics, however various forms of the kappa 
statistic are described: unweighted and weighted (linear or quadratic). 
The weighted kappa values give an overall assessment of variability, penalizing 
large discrepancies more than smaller. The unweighted kappa values however 
reflect disagreement irrespective of the magnitude of disagreement, and small 
discrepancies are penalized to the same extent as larger discrepancies. The 
weighted kappa therefore usually exhibits more favourable agreement than the 
unweighted kappa, smaller discrepancies not affecting the overall kappa to the 
same extent. Assessment of both measures is important, as a mere assessment of 
weighted kappa may give a false impression of low variability. Consider most 
trials on thrombolysis, where the outcome studied has been a dichotomization 
of the mRS, one common threshold being mRS grade 2. Differentiating between 
grade 2 and 3 can sometimes be difficult, the highest rate of disagreement 
occurring in the middle region of the score, whereas score assignment at the two 
ends usually is considered more straightforward (172, 173). Choosing a dichotomy 
as an endpoint in a clinical trial, especially at a grading threshold where 
disagreement may be highly significant, can pose serious problems, increasing 
the risk of type II-errors.  
 
The choice of how to analyse the mRS as an endpoint in clinical trials has 
received increasing attention, partly due to concerns over the risk of missing true 
treatment effects in major clinical trials. An example are the results from the 
ECASS II trial, in which the primary endpoint, a dichotomization at mRS£1, 
yielded a negative result, while post-hoc analysis extending the dichotomization 
to mRS £2 yielded a result statistically in favour of iv-tPA (157). Dichotomizations 
restrict assessment of outcome transition to one specific level, favourable 
transitions at other levels going undetected. In order to address this problem, 
several newer statistical methods for outcome analysis have been proposed, 
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including the global statistic, responder analysis and shift analysis (174). Briefly, 
shift-analysis assesses changes in outcome distribution over the entire range of 
the mRS, instead of at specific cut-offs. This improves the possibility of detecting 
relevant treatment effects. An example of this is the IST-3 trial which as a 
primary outcome used a dichotomy of the Oxford Handicap Scale (a 
modification of the original Rankin Scale, basically identical to the mRS despite 
a somewhat different wording). The study was negative using the dichotomized 
primary outcome, however a secondary endpoint employing shift analysis 
showed a statistically significant shift in odds ratios in favour of iv tPA (101). A 
highly interesting study by Jeffrey Saver, assessing the results from several mock 
trials employing both shift analysis and dichotomizations, in general supported 
shift analysis over dichotomy. However, in certain situations in which a therapy 
is predicted to cause major changes in the distribution of the outcome mRS, such 
as early and late recanalization trials, dichotomized analysis at mRS  £ 1 or mRS 
£ 2 might be more appropriate (175).  
 
The evolution of statistical reasoning in the setting of acute stroke trials is 
evidenced by the increasing frequency of shift analysis in recent trials on 
mechanical thrombectomy. Outcome analysis needs to be tailored to the specific 
treatment and population under investigation.  
 
Finally, a few words regarding timing of outcome assessment. In one of the 
above-mentioned reviews investigating the most commonly used outcome 
assessments in clinical trials, the most common time-frame for outcome 
assessment was 3 months (137). For severely affected patients, spontaneous 
improvement may not level off until five or six months’ post-stroke. Therefore, 
outcome assessment could if possible be performed at a later time-point. This is 
however a trade-off against the sensitivity of detecting relevant treatment-
caused changes, as there may be an increased risk of other factors not connected 
to the administered stroke therapy affecting outcome with a longer elapsed time.   
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1.7.2 Modified Rankin Scale - alternative methods of assessment 
In a large meta-analysis summarizing data from 126 trials involving 
interventional studies in stroke patients between 2001 and 2006, the 
methodologies for assessment of stroke functional outcomes were described. For  
 
a majority of trials (73.2%), no description of methodology was given, while 
telephone interviews were most common among the studies where details of 
methodology were available. Other methodologies used included face-to-face 
interviews (likely the most common assessment overall), case-sheet reviews, 
postal surveys, questionnaires and structured interviews, see Figure 21. 
Studies validating the performance of these alternative assessment 
methodologies are limited. A couple of studies have investigated the role of mRS 
telephone assessment with mixed results (172, 173, 176-178).  
 
A major drawback limiting the possibility of properly assessing these studies are 
inconsistencies in the statistical methods used, some studies reporting only 
weighted kappa values, some only un-weighted kappa values and only a few 
both. Most of the studies were relatively small with low numbers of included 
patients. One study found a poor inter-rater-variability when comparing 
telephone interviews with face-to-face interviews with an un-weighted kappa 
value of 0.30-0.38 (172). Two other studies have found more promising results 
with higher weighted kappa results, ranging from 0.71-0.89 (176, 178). Yet the 
same studies showed relatively low un-weighted kappa results close to 0.4. 
Although telephone mRS assessments may not be able to replace traditional 
visits completely, they may have a role in certain circumstances.  
One study assessed the role of mRS derivation using case-records from standard 
hospital records compared to face-to-face interviews, showing poor results (179). 
Another study assessed the performance of a simplified mRS questionnaire 
(smRSq), reporting a promising weighted kappa of 0.82 between two raters using 
the smRSq (180). The smRSq was further tested in a study comparing postal 
questionnaires based on the smRSq with telephone RFA-based assessments. The 
reported agreement between postal smRSq and telephone interviews was 
 
Figure 21. Methods for 
collecting functional 
outcomes data. From a large 
meta-analysis. Reproduced 
from Quinn et al, 2009 (134). 
Permission for use obtained 
from SAGE Publications. 
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weighted kappa 0.73 and unweighted kappa 0.55 (181). A major limitation of the 
smRSq studies is the lack of validation of the new proposed methods, the studies 
assessing reliability but merely assuming validity and not comparing with 
traditional face-to-face mRS assessments. 
 
In summary, alternative methods for assessing the mRS are probably wide-
spread, the exact extent uncertain because of a poor description in the methods 
sections of most articles. The studies investigating these alternative assessments 
are unfortunately generally small-scale studies, and in several cases validity has 
not been ascertained by comparison with traditional face-to-face interviews. 
 
In the SITS-ISTR stroke register, on which three of the sub-studies in this thesis 
are based on, there is an approximately 20-25% frequency of missing outcome 
assessments at 3 months. In order to find ways of bridging this void of missing 
outcome data, we have evaluated a new mobile phone-based questionnaire for 
self-assessment of the mRS after acute stroke (138).  
The results from this fourth study of the present thesis will be presented and 
discussed later. 
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1.8 PREDICTING FUNCTIONAL OUTCOME IN ACUTE STROKE 
Stroke is a multifactorial disease, and the most common underlying causes and 
risk factors such as hypertension, hyperlipidemia, older age, diabetes mellitus, 
smoking and cardiac disease among others are well-known and have been 
extensively studied (182). We will here, however, focus the discussion on the 
parameters and risk factors associated with long-term functional outcome once 
the ischaemic stroke has become an established fact. The association between 
various parameters in the acute setting of ischaemic stroke and long-term 
functional outcome have been extensively investigated, and several prediction 
rules and models have been proposed. An article from 2015, reviewing the 
currently available models predicting functional outcome after acute ischaemic 
stroke, has illustratively summarized the most commonly included parameters, 
see Figure 22 (183).  
 
 
Figure 22A is a Venn diagram summarizing parameters predicting outcome in 
unselected ischaemic stroke cohorts, and Figure 22B summarizes parameters 
predicting outcome in iv-tPA treated patients. In the coming sections the most 
commonly used parameters will be discussed in detail. At first, parameters 
common to both the unselected and thrombolysed cohorts will be reviewed, 
followed by a discussion on parameters specifically relevant for iv-tPA treated 
stroke cohorts. 
 
We will now discuss these parameters in more detail. 
 
 
  
Figure 22A/B. Venn diagrams illustrating the included parameters in models predicting 
functional outcome after acute ischaemic stroke. Each eclipse represents a specific model.      
A) Models predicting functional outcome in unselected ischaemic stroke cohorts. B) Models 
predicting functional outcome in iv-tPA treated patients Reproduced from Ntaios et al, Stroke 
2015 (183). Permission obtained from Wolters Kluwer Health. 
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1.8.1 Predictive parameters in ischaemic stroke patients (unselected) 
 
1.8.1.1 Stroke severity 
As discussed in a previous section of this thesis, the NIHSS score is the most 
widely recognized and utilized scale for assessing baseline stroke severity, 
showing an acceptable inter-rater variability both for expert neurologists and 
general users (184). Clear associations between baseline NIHSS scoring and long-
term outcome were already demonstrated in the original NIHSS article by Brott 
et al, in which a Spearman correlation coefficient of 0.53 between scoring and 3-
months outcome was seen (the statistic ranges -1 to 1) (139). Further studies have 
confirmed the severity of stroke, measured in the acute setting of the disease, as 
the most important determinant of long-term functional outcome in acute 
stroke (145, 139, 185, 186, 161, 187, 188). This trend is also seen in iv-tPA treated 
patients, as demonstrated in the large IPD by Emberson et al, as well as in 
patients treated with mechanical thrombectomy, as seen in the IPD by Goyal et 
al (102, 129). Important to note, the effect of treatment, whether iv-tPA or 
mechanical thrombectomy, is similar across a wide range of stroke severity.  
 
The predictive value of stroke severity on functional outcome is clearly 
established, stroke severity in the majority of cases being measured using the 
NIHSS. Drawbacks of the NIHSS include its complexity, necessitating 
assessment of 15 different items. Most studies investigating the predictive role of 
stroke severity on long-term functional outcome, including the first project of 
this thesis, have examined the NIHSS in its total sum (in some cases categorized, 
in other cases examined as a numerical variable), however not specifically 
studying the predictive performance of individual sub-items. We will therefore 
briefly discuss the outcome validity of individual NIHSS score items. Already in 
the original NIHSS article, certain sub-items were shown to display a low 
reliability, including limb ataxia, facial palsy, dysarthria and level of 
consciousness (139). A most interesting analysis by Lyden et al. from 1999 
investigated the underlying structure of the NIHSS (141). This study found 4 
main “factors” that represented the NIHSS, interpreted as left and right cortical 
function, and left and right motor function. Each sub-item of the 15-item NIHSS 
“loaded” on one of these 4 factors, it was however shown that items ataxia, facial 
motor function and level of consciousness (LOC 1A) either loaded poorly or were 
redundant. These observations sparked the development of a modified NIHSS, 
mNIHSS, where poorly reliable/redundant sub-items including level of 
consciousness, facial palsy, dysarthria and ataxia were removed (189). This 
mNIHSS was shown to carry a similar prognostic value regarding long-term 
functional outcome as the original 15-item NIHSS, both in a retrospective as well 
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as a prospective study (189, 190). Another interesting study examining the 
predictive value of individual NIHSS sub-items creating multivariable models for 
predicting long-term outcome in stroke, found the following items as most 
predictive: right lower extremity motor function, left lower extremity motor 
function, gaze, visual fields, aphasia, level of consciousness, facial motor 
function and dysarthria. This simplified scale was termed sNIHSS-8, and a 
further refinement termed sNIHSS-5 only kept the five most predictive items. 
Both the sNIHSS-8 and sNIHSS-5 retained much of the predictive value of the 
full 15-item NIHSS (191). A Swedish study by Appelros and Terént from 2004 
identified level of consciousness items and motor leg functions as most 
predictive of long-term functional dependency (192). The importance of 
individual sub-items in prediction was further strengthened in an analysis by 
Sucharew et al, where a statistical technique called “Latent Class Analysis” was 
used to group stroke patients into profiles with similar sub-item phenotypes. 
This study found 6 different profiles, A-F, where profile A had the highest 
probability of deficits in several NIH sub-items including level of consciousness, 
whilst profile E and F included patients with milder deficits. Despite having 
similar median total NIHSS score values, profiles C and D differed significantly 
in outcome, the main difference being profile C representing more patients with 
aphasia  (193). The importance of considering individual NIH sub-items in 
addition to the total sum NIHSS score is evident. 
 
One of the main aims of project 1 in this doctoral thesis was the identification of 
thresholds on the baseline NIHSS for predicting long-term functional outcome. 
Few studies have specifically examined NIHSS threshold values for predicting 
functional outcome in acute stroke. Optimum cut-offs for predicting long-term 
unfavourable functional outcome at NIHSS scores of 13, 16 and 17 have been 
presented in these studies (145, 194, 195). Importantly, patients in these studies 
were not treated with iv-tPA. Regarding iv-tPA treated patients, one smaller 
study (108 iv-tPA treated patients) did not find a good predictive value (AUC 
0·634) of the baseline NIHSS in predicting poor functional outcome (196). 
Patients in that study had a high stroke severity (median NIHSS 17), and 
excluded patients with NIHSS ≤ 7 as well as absence of occlusion on MR 
angiography. The results of the findings from the first project of this theses will 
be discussed in the context of the currently available evidence later on in the 
Discussion section. 
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1.8.1.2 Age 
Age at stroke-onset is alongside with stroke severity one of the strongest 
predictors of functional outcome after stroke. Numerous studies have 
investigated this relationship, confirming the inverse relationship between 
increased age and good functional outcome after stroke (197, 198, 192, 185). One 
study found a steady decrease in chance of good functional outcome from age 
strata 18-35 to 75, with an average decrease of 3.1%-4.2% per decade, with a steep 
decrease seen after 75 years of age (197).Importantly, increasing age shows a clear 
inverse association with favourable 3-months functional outcome in 
thrombolysed patients as well (199, 200, 100). However, age does not affect the 
relative effect of thrombolysis compared to control (102, 101, 103, 99). There has 
been considerable debate as to the efficacy of iv-tPA in older patients, the large 
individual patient data meta-analysis by Emberson et al from 2014 (including the 
large IST-3 trial) clearly showing that patients >80 years show a proportionally 
similar benefit from iv-tPA as compared to younger patients, albeit in absolute 
numbers having a higher proportion of patients with poor functional outcome 
(102). 
 
1.8.1.3 Hyperglycaemia 
Previous studies have found that approximately 60% of all acute ischaemic 
stroke patients suffer from hyperglycaemia at some point after stroke-onset 
(201). A systematic review from 2001 summarized the findings from several 
previous studies and concluded the increased risk of poor functional recovery in 
non-diabetic patients with hyperglycaemia at stroke presentation. The same 
review could not ascertain the detrimental effects of hyperglycaemia on long-
term functional outcome in diabetic patients, (202). The detrimental effects of 
baseline hyperglycaemia and increasing baseline glucose concentration on 3-
months functional outcome after iv-tPA treated ischaemic stroke, both diabetic 
and non-diabetic, are well established (203, 204). However, no randomised 
clinical trial to date has shown a benefit of intensive insulin therapy in the acute 
setting of stroke, the largest of these the negative GIST-UK trial which enrolled 
933 patients (205). 
The underlying mechanisms leading to the detrimental effects of 
hyperglycaemia include among other glucose-mediated increase in oxidative 
stress and inflammation (206), upregulation of thrombin-antithrombin 
complexes (207) and reduced cerebral blood flow due to inhibited vasodilation 
(208). The effects of hypoglycaemia in humans show conflicting results (209). 
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1.8.1.4 Gender 
Previous studies have shown gender differences in the presentation, severity of 
stroke and long-term functional outcome. In general females present at a higher 
age with a higher stroke severity and more cortical symptoms (210). Review 
studies summarizing the findings from previously conducted studies have 
consistently shown a higher rate of 3-month dependency among women (210, 
211), in part but not completely explained by differences in stroke-severity and 
age at stroke-onset. The natural history of stroke seems to be in a disadvantage 
for women considering long-term functional outcome (212, 213).However, 
interestingly several studies examining the gender effect in iv-tPA treated 
patients show no difference in 3-months functional outcome between the sexes 
(214-216). It appears that iv-tPA reverses the natural history of ischaemic stroke, 
efacing the differences in outcome between the two sexes. 
 
1.8.2 Predictive parameters in ischaemic stroke patients (iv-tPA treated) 
1.8.2.1 Imaging 
In the hyperacute assessment of stroke patients, radiologic assessment of 
cerebral tissue and vascularization is a cornerstone of the diagnostic workup. 
Even though various techniques based on magnetic resonance imaging (MRI) 
have a higher sensitivity and specificity for detecting acute ischaemic changes 
compared to computer tomography (CT), as evidenced by a sensitivity of 75% on 
CT compared to MR-DWI for detecting acute ischaemic changes (217), CT still 
remains the most common mode of assessment of stroke. A systematic review 
from 2005 investigating the association between early changes on CT 
(hypoattenuation of MCA territory, obscuration of lentiform nucleus, cortical 
sulcal effacement, focal hypoattenuation, hyperattenuation of vessel etc.) and 
long-term clinical outcome found a combined odds ratio of 3.11 (95% CI 2.77-
3.49) for poor functional outcome. The review could not leave any guidance as 
to which specific sign was most predictive, and did not find any effect of iv-tPA 
on the association between infarct changes and outcome (218). Data from the 
largest RCT on iv-tPA in acute ischaemic stroke, IST-3, did not find a detrimental 
effect of iv-tPA on outcome in patients with any infarct changes (101). Important 
to mention however, specific infarction of more than 1/3 of the MCA territory 
was found to be associated with large SICH after iv-tPA in a review from 2008 
(219). 
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A small study on 22 acute ischaemic stroke patients with MCA occlusion treated 
with intra-arterial thrombolysis found a clear association between perfusion 
deficits on perfusion weighted CT scans and long-term outcome (220). 
The hyper-dense middle cerebral artery-sign (see Figure 23) is one of the early  
 
signs of a large arterial occlusion and is seen on non-enhanced CT-scans in the 
acute setting, prevalent in about 20% of all patients registered in the SITS-ISTR 
(221). In this paper presence of the sign was associated with a median NIHSS of 
17, twice the mortality and half the frequency of functional independence 
compared to patients without the sign. In a most recent article published in 
Neurology 2015, analysis of patients from the IST-3 were performed, comparing 
subjects with and without the dense-artery sign (222). The presence of the sign 
independently predicted poor 6-month outcome (OR 0.66), however there was 
no evidence of a difference in effect of iv-tPA on outcome irrespective of 
presence or absence of the sign. 
New MRI techniques such as MR diffusion weighted imaging (MR-DWI) in the 
acute setting of stroke have been shown to carry independent prognostic value 
on long-term functional outcome after stroke (186, 223). A study from 2010 
showed that MR-DWI, applied as DWI-ASPECTS scores in the acute setting of 
stroke, independently predicted functional outcome at 3 months (224). Other 
studies have found clear associations between long-term outcome in iv-tPA 
treated patients and both pre-thrombolysis MR-DWI lesion volumes as well as 
reductions in hypoperfusion volume (pre- and 2h post iv-tPA) measured on 
mean transit time (MTT) maps (225, 162). 
 
 
 
Figure 23. The hyperdense middle-
cerebral artery sign. From 
Radiopaedia.org. No permission 
required, in the public domain. 
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1.8.2.2 OTT (Onset to treatment) 
The effect of iv tPA on outcome is time-dependant, the theoretical base being 
the increasing conversion of ischaemic penumbra to infarct as time proceeds. A 
pooled analysis of several RCTs on stroke thrombolysis published 2010 in the 
Lancet (98), showed an increasing Number Needed to Treat (NNT) for achieving 
mRS 0-1 as OTT increased.  During the first 1.5 h, NNT was 4.5, between 1.5-3h 
NNT 9 and between 3-4.5h NNT 14, see table 1. Figure 12 illustrates the time-
dependence of iv-tPA treatment on favourable outcome. The same trend was 
seen in a previous pooled analysis published in 2004 (93). An increased onset-
to-treatment time with iv-tPA in acute ischaemic stroke was clearly associated 
with reduced 3-months favourable outcome in the meta-analysis by Emberson 
et al in 2014, comparing iv-tPA with placebo (102). 
 
1.8.2.3 Blood Pressure 
High blood pressure in the acute setting of stroke is associated with long-term 
death and dependency (226). Data from the International Stroke Trial 
(IST)showed a U-shaped relationship between baseline systolic blood-pressure 
and long-term death and dependency, the most favourable baseline blood-
pressure being around 150 mmHg (227). A subsequent review study including 
close to 11000 patients confirmed the relationship between both high systolic, 
diastolic and mean arterial blood pressures and death and dependant functional 
outcome  (228).   Regarding post-thrombolysis levels of blood pressure, a study 
from the SITS group showed an inverse U-shaped relationship between post-
thrombolysis (within 24 hours) blood pressure and 3-month functional outcome, 
patients with systolic blood-pressure between 141-150 mmHg showing the 
highest proportion of functional independency, in line with the data from IST, 
see Figure 24 (229). 
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The relationship between pre-thrombolysis blood-pressure and long-term 
outcome were not equally clear in this study. The same study suggested a more 
active approach to blood-pressure lowering than current guidelines, as did an 
analysis of IST-3 data (230). Despite these observational data, no large RCT to 
date has shown any benefit of blood pressure lowering therapy in the acute 
setting of stroke (231, 232). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Association between post-
thrombolytic systolic blood-pressure (x-
axis) and odds-ratio for functional 
independency (y-axis). Reproduced from 
Ahmed et al, Stroke 2009 (229). Permission 
for use obtained from Wolters Kluwer 
Health. 
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1.9 EXISTING MODELS FOR PREDICTING FUNCTIONAL 
OUTCOME 
As outlined above, several individual parameters have been associated with 
functional outcome in acute ischaemic stroke, both in untreated as well as in iv-
tPA treated patients.  
Prediction of outcome after AIS may serve several purposes (183):  
 
1) Early prognostication may aid patients and caregivers in planning long-
term living arrangements 
2) May be implicated in treatment decisions, such as de-escalating 
treatment in patients with a predicted excellent outcome regardless of 
treatment or in patients with a predicted poor outcome despite 
treatment. 
3) Prediction may be used in research and trial settings for selection of 
patients with the highest chance of benefitting from the investigated 
treatment, which could reduce required sample size and eliminate “noise” 
created by patients with a low likelihood of benefit. 
 
Prediction based on singular parameters may increase the risk of missing 
important predictive information, a multivariable consideration may give a more 
balanced and accurate prediction for the individual patient. Prognostic models 
however need to be simple, including only a few important but readily available 
parameters applicable in the clinical setting, easily reproducible with a high 
reliability, validated in various cohorts for increased generalizability and finally 
shown to improve clinical decision making. The demands on the optimum 
predictive model/risk score/prognostic model/prediction rule are high, and a 
guide toward the development of high-quality models has been outlined in a 
highly informative and appreciable article series by Moons, Altman and Royston 
et al (233-236). Several studies have been published aiming at developing models 
for predicting functional outcome after stroke. These studies can be divided into 
two groups, on the one hand studies predicting outcome in unselected acute 
ischaemic stroke patients, and on the other hand in patients treated with iv-tPA. 
As to prediction of functional outcome in acute ischaemic stroke patients 
undergoing endovascular therapies, predictive models have been proposed, 
however this discussion is beyond the scope of this thesis (237). Tables 3 and 4 
summarize the currently existing predictive models for unselected and iv-tPA 
treated patients respectively. 
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Model/Score Included variables 
ASTRAL Age, Stroke-severity, Onset-to-Admission-
time, Visual field defect, Glucose on 
admission, Level of consciousness 
BOAS Age, Stroke-severity, Persistent upper limb 
paralysis, Need for O2 administration, Need 
for urinary catheter 
GWTG Age, Stroke-severity, Mode-of-arrival, 
Gender, CVD risk-factors, Co-morbidities. 
iScore Age, Stroke-severity, Stroke-subtype, Gender, 
CVD risk-factors, AF, CHF, MI, Smoking, Co-
morbidities. 
PLAN Age, Neurological deficit, Level of 
consciousness, Co-morbidities. 
SSV Age, living alone pre-stroke, pre-stroke 
disability, normal GCS verbal score, Arm-
paresis, Walking ability. 
Wang et al Consciousness, Dysphagia, Urinary 
incontinence, Body-temperature, 
Hyperglycemia. 
Weimar et al. Age, Stroke-severity. 
Table 3. Prognostic models for unselected acute ischaemic stroke populations. 
 
Models for prediction of outcome in unselected ischaemic stroke patients 
include: The ASTRAL score (238), the BOAS score (239), the GWTG risk score 
(240), the iScore (241), the PLAN score (242), the SSV score (243), the Prognostic 
Index by Wang et al (244)and finally the prognostic model by Weimar et al (245).  
Models for prediction of outcome in iv-tPA treated patients include: The stroke 
thrombolytic predictive instrument, TPI (246), MOST (247) and DRAGON (248). 
 
Model/Score Included parameters 
TPI for good outcome Gender, Systolic Blood-Pressure, Previous 
stroke, Onset-to-treatment time, Iv-tPA 
TPI for catastrophic outcome Age, Stroke-severity, Glucose, ASPECTS-
score 
MOST Stroke-severity, Proximal occlusion, Systolic 
Blood-Pressure, Recanalization 
DRAGON Age, Hyperdense cerebral artery sign/Early 
Infarct Changes, Prestroke mRS, Glucose, 
Stroke-severity, Onset-to-Treatment time. 
Table 4. Prognostic models for thrombolysed acute ischaemic stroke populations. Created by the 
author of this thesis. 
 
I will now very briefly summarize these predictive models, where possible 
mentioning the development of the model, validation and where applicable 
possible impact that the scale may have on clinical decision making.  
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1.9.1 Predictive models in unselected ischaemic stroke patients 
ASTRAL-score (238): Included parameters- Age, Stroke-severity, Onset-to-
Admission-time, Visual field defect, Glucose on admission, Level of consciousness. 
This simple model not requiring an advanced calculation was developed on an 
unselected cohort of 1645 previously independent ischaemic stroke patients. The 
score ranged from 5-63 in the original study, median 23, increasing scores 
representing increasingly poor functional outcome (mRS>2). The area under the 
curve (discriminative capacity) was 0.850 in the derivation cohort and validation 
in two separate cohorts in the original article resulted in AUCs of 0.771 and 0.937 
respectively. Subsequently, the ASTRAL score was validated in a Chinese cohort 
with promising findings (AUC 0.82) (249) and in a Greek cohort investigating 
functional outcome at 5 years (AUC 0.89) (250). The first validation in an iv-tPA 
treated cohort was study 2 of this thesis, showing an AUC of 0.790 (251). No 
imaging data are included in the original score, and a subsequent study did not 
find an improvement of the scores accuracy after addition of multimodal acute 
imaging data (252).  
 
BOAS score (239): Included parameters- Age, Stroke-severity, Persistent upper 
limb paralysis, Need for O2 administration, Need for urinary catheter. 
This simple model not requiring an advanced calculation was developed on 221 
ischaemic stroke patients and validated on 100 patients. AUCs in derivation and 
validation cohorts were 0.891 and 0.839 respectively. The major drawback is that 
the score assesses the parameters at discharge, not in the acute setting, 
complicating acute assessment of outcome. Included score parameters such as 
upper limb paralysis may change during the course of the hospital stay. To my 
knowledge no external validation has been performed. 
 
GWTG (240): Included parameters- Age, Stroke-severity, Mode-of-arrival, Gender, 
CVD risk-factors, Co-morbidities. 
This risk score was developed on a very large unselected ischaemic stroke cohort 
for predicting in-hospital stroke mortality (total patient cohort nearly 275 000). 
It requires a mathematical calculation for risk prediction, necessitating a 
calculator or access to the score internet site. The score was internally validated 
in the original article with a C-statistic of AUC 0.72, and a sub-analysis including 
stroke severity measured using the NIHSS resulted in a model with AUC 0.85. 
Significant individual predictors after adjustment for stroke severity included 
mode of arrival, age, atrial fibrillation, female sex, dyslipidaemia and previous 
myocardial infarction. A model only including the NIHSS resulted in an AUC of 
0.83. The model has been validated in a large Chinese stroke cohort, AUC 0.87, 
a model only including the NIHSS showing a AUC of 0.85. This external 
validation showed excellent calibration (253). Drawbacks could be differences in 
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in-hospital duration and care in different geographic and clinical settings which 
would affect the results, as a fixed point of outcome assessment was not defined. 
Further, the model predicts mortality, not long-term functional outcome, the 
main measure of outcome investigated in this thesis. 
 
Iscore (254): Included parameters- Age, Stroke-severity, Stroke-subtype, Gender, 
CVD risk-factors, AF, CHF, MI, Smoking, Co-morbidities. 
The Iscore was originally developed on a large ischaemic stroke cohort (12262 
patients) for predicting 30-day and 1-year mortality. It showed a good AUC for 
both outcomes in the derivation cohort (AUC 0.85 and 0.82 respectively) and 
AUC 0.79 and 0.78 in the external validation cohort of the original study. Score 
calculation demands the use of a web application, and predicted outcome can 
be assessed from available risk-stratification bar-charts. The score was 
subsequently validated for 30-day mRS>2 with different patients from the same 
registries used in the development of the model. High correlations between 
observed and predicted outcome were seen (241). The Iscore has been 
extensively validated for long-term functional outcome, both in unselected and 
iv-tPA treated cohorts, showing promising results (255-257). Few scores have 
been assessed for predictive capability compared to informal clinician 
prediction, and the Iscore is one of few scores that has actually shown a better 
prediction of long-term outcome compared to clinician prediction (258). 
Though externally validated and showing promising results, one important 
drawback limiting its use is the stroke severity measurement used, the Canadian 
Neurological Scale, which in current practice has been increasingly replaced by 
the NIHSS. Another important limitation is the complexity of the model. 
 
PLAN (242): Included parameters- Age, Neurological deficit, Level of 
consciousness, Co-morbidities. 
This simple score was developed for the assessment of severe disability or death 
at discharge, as well as 30-day and 1-year mortality. A post-hoc analysis for 
prediction of discharge functional outcome resulted in a C-statistic of 0.80. For 
assessment of prognosis bar-charts from the original article can be used. Instead 
of using a formalized stroke severity instrument, sole assessment of paresis and 
language/neglect is performed, which may be attractive for non-neurologist 
physicians assessing outcome. In the original study, poorer results for iv-tPA 
treated patients were seen, reducing the generalizability of the score. To our 
knowledge no external validation has been performed.   
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SSV (243): Included parameters- Age, living alone pre-stroke, pre-stroke disability, 
normal GCS verbal score, Arm-paresis, Walking ability. 
This model for predicting 30-day survival and 6-months functional 
independence (Oxford Handicap Scale score<3) showed promising results in 
internal validation cohorts (AUC 0.84-0.88). Calibration was reasonable, 
however overoptimistic in patients with the highest predicted probability of 
functionally independent outcome. No details on how to calculate the score were 
given (however details were subsequently described in a validation study by the 
original authors, revealing a fairly complex score calculation) (259). Score 
assessment was performed within 30 days, hindering its use for prognostication 
in the hyper-acute phase of stroke where most therapeutic decisions are made. 
Subsequent external validation however showed promising results in hyper-
acute patients as well (260, 261). In my opinion, important limitations of this 
model include the complex calculation needed for prediction, as well as the 
inclusion of prestroke disability rated on the Oxford Handicap Scale (essentially 
the same assessment as the modified Rankin Scale). One study suggested a low 
validity of pre-stroke mRS assessment, the wording of the categories of the mRS 
not suiting for pre-stroke assessment (262). In addition, one study investigating 
the performance of the SSV among other stroke prognostication scales found no 
significant difference between informal clinician predictions of outcome 
compared to the prediction model (263). 
 
Prognostic index by Wang et al (244): Included parameters- Consciousness, 
Dysphagia, Urinary incontinence, Body-temperature, Hyperglycemia. 
Prognostic model for 30-day mortality, score ranges from 0-16. The authors 
proposed a cut-off of ³11 as the optimum threshold, higher scores associated with 
75% risk of death, and lower scores only 3%. To my knowledge, the score has 
subsequently not been validated, and important drawbacks include lack of a 
formal and broad assessment of stroke severity, the parameter recognized as 
bearing the highest predictive value regarding outcome in stroke. 
 
Prognostic model by Weimar et al (245): Included parameters- Age, Stroke-
severity. 
This is the first prediction model showing the predictive value of stroke severity 
measured by the NIHSS and age as most important predictors of incomplete 
functional recovery (measured on the Barthel Index) in the hyper-acute setting 
of stroke. AUC in the internal validation cohort amounted to 0.86. Details in the 
original study enable future prediction of outcome in new patients, however a 
complex calculation is needed for this assessment. In the original study the 
model predicted outcome better than informal clinician prediction, however 
subsequent studies found no significant difference between informal clinician 
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predictions of outcome compared to the prediction models (263) The model has 
been validated in the large Virtual International Stroke Trials Archive (VISTA) 
with promising results (AUC 0.81) (188). Major drawbacks are the use of the 
Barthel Index for outcome assessment, limiting comparison with models using 
the more common mRS, as well as a complicated calculation needed for outcome 
prediction. 
 
1.9.2 Predictive models in iv-tPA-treated ischaemic stroke patients 
TPI (246): Included parameters in favourable outcome model- Gender, Systolic 
Blood-Pressure, Previous stroke, Onset-to-treatment time, Iv-tPA. Included 
parameters in catastrophic outcome model- Age, Stroke-severity, Glucose, 
ASPECTS-score. 
The Stroke Thrombolytic Instrument was developed on patients from 5 large 
RCTs on iv-tPA within 0-3 h in acute ischaemic stroke, and consisted of two 
models aiming at predicting a favourable 3-month outcome (mRS£1) and a 
catastrophic outcome (mRS³5) in the presence/absence of iv-tPA, in order to 
help clinicians in treatment decisions. Prediction assessment is dependent on a 
handheld or internet access to the instrument internet site.  In the original 
article, AUCs of 0.79 and 0.77 for the two outcomes respectively were described. 
The first model, as seen in table 4, includes neither age nor stroke severity, the 
two parameters now widely recognized as the most important predictors of 
outcome. However, the second model predicting a catastrophic outcome does 
include these parameters. Subsequent external validation of the instrument 
revealed a tendency for overestimating good outcome and underestimating poor 
outcome (264, 265), one of these studies showing improved prediction of a 
favourable outcome when signs of brain infarction was added as a predictive 
variable. This was probably due to at least partially resolving the issue of the 
original model lacking a measure of stroke severity (264).  
 
MOST (247): Included parameters- Stroke-severity, Proximal occlusion, Systolic 
Blood-Pressure, Recanalization. 
This highly interesting predictive model was developed with the aim of finding 
clinical and radiological predictors apart from early recanalization after 
thrombolysis that could predict a favourable 3-months outcome (mRS £2). The 
model found increasing stroke severity, early infarct changes on CT, proximal 
occlusion and systolic blood pressure as most important variables apart from 
early recanalization for predicting a favourable long-term outcome. Scores 
ranged from 0-7, and at a cut-off of <4, a sensitivity and specificity of 77% and 
82% respectively was seen. AUC for the model was 0.862. Of all predictive 
models discussed above, this is the only model specifically incorporating 
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proximal vessel occlusion as a predictor of outcome (this association will be 
further scrutinized in section 1.10). In this study, Transcranial Doppler 
ultrasound (TCD) was the modality used for vascular imaging, and an important 
drawback would be the need for imaging of the cerebral vasculature not available 
at all centres. To our knowledge, the model has not undergone any external 
validation. 
 
DRAGON (248): Included parameters- Age, Hyperdense cerebral artery sign/Early 
Infarct Changes, Prestroke mRS, Glucose, Stroke-severity, Onset-to-Treatment 
time. 
The DRAGON score, a simple integer score used in conjunction with a simple 
outcome chart, was developed in a single-centre cohort of acute ischaemic 
stroke patients treated with iv-tPA, using multivariate logistic regression 
analysis for predicting 3- months favourable outcome (mRS£2). It consists of 7 
parameters, two of which require an admission brain CT scan (early infarct signs 
and/or presence of the dense vessel sign). The score ranges from 0 to 10, 
increasing scores associated with a decreasing chance of a favourable outcome. 
Discrimination assessed by the C-statistic was good, 0.84 in the development 
cohort (1319 patients) and 0.80 in a smaller external validation cohort (333 
patients). The DRAGON score has been validated in 3 separate studies showing 
promising results (266-268). The largest validation so far was in the second 
project of this thesis, AUC 0.77 (251). An alteration of DRAGON, replacing CT-
imaging with MRI, had a similar performance and was subsequently validated 
with good performance (269, 270). Although predicting outcome reasonably 
well, the DRAGON does not serve a purpose in the prehospital setting due to the 
need of imaging data. 
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1.10 ARTERIAL OCCLUSION AND FUNCTIONAL OUTCOME 
In the preceding section, we have inter alia discussed the relationship between 
stroke severity and outcome, and in the coming sections the relationship 
between stroke severity and presence of arterial occlusion will be discussed as 
this may have important implications for pre-hospital decisions on proper triage 
of patients. However, prior to this discussion, a short review of the association 
between the presence of arterial occlusions and long-term functional outcome 
is in place, in order to fully appreciate the interplay between stroke severity, 
presence of arterial occlusion and long-term outcome. 
 
As already described, stroke severity is probably the most important 
determinant of long-term functional outcome in acute ischaemic stroke. As we 
will see in the coming sections, clear correlations exist between increasing stroke 
severity and presence of LAO in the acute setting as well. The heart of the matter 
is whether LAO in itself carries predictive value, independent of stroke severity, 
in predicting long-term functional outcome. The MOST score from 2004, 
described above, found that the presence of a proximal occlusion on the MCA, 
identified on TCD, predicted functional outcome at 3 months in patients treated 
with iv-tPA independently of stroke severity (247). This analysis was based on a 
small cohort of 177 patients. A similar sized study from 2006 studying ischaemic 
stroke patients examined with CTA showed how intracranial LAO predicted 
discharge functional outcome with an OR of 4.5, independently of stroke 
severity. Presence of a LAO conferred a similar OR for functional outcome as an 
8p increase on the NIHSS score (55). The authors of the latter study subsequently 
published a paper based on over 700 unselected ischaemic stroke patients 
undergoing CTA. In univariate analysis, presence of a LAO negatively predicted 
6-months outcome (OR 0.33). In multivariable analysis, presence/absence of ICA 
terminus or basilar occlusion was independently associated with the outcome 
(53). In 2007, Nedelchev et al published the results from an interesting study 
aiming at finding predictors of poor outcome in patients with mild or rapidly 
improving symptoms eligible for iv-tPA but not treated due to a perceived 
likelihood of a favourable course without treatment. The presence of a LAO and 
NIHSS³10 were independent predictors of a poor outcome, and the presence of 
LAO increased the risk of a poor outcome by more than 7-fold (271).  
 
Finally, a meta-analysis from 2015, covering 39 different studies, showed clear 
correlations between proximal arterial occlusion and a poor functional outcome 
in patients treated with iv-tPA. The OR for a favourable outcome (mRS£2) was 
0.24 comparing ICA occlusions (exact site not specified) with isolated MCA 
occlusions (272). Although stroke severity and vessel occlusion are closely 
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correlated, patients with similar sites of vessel occlusions may present with 
varying stroke severity. Other vascular factors such as variations in collateral 
circulation play an important role in the final outcome of patients with occlusive 
acute ischaemic stroke. 
 
In summary, arterial occlusion carries a predictive value on long-term functional 
outcome, independent of initial stroke severity. We will now proceed to the final 
part of this thesis introduction, where the associations between stroke severity 
and vessel occlusion will be scrutinized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		60	
1.11 PREDICTING ARTERIAL OCCLUSIONS IN ACUTE ISCHAEMIC 
STROKE 
We will now mainly discuss the predictive value of baseline stroke severity on 
the presence of arterial occlusion, owing to the established beneficial effects of 
thrombectomy within 6h in anterior circulation stroke and the need for swift 
and proper patient selection. Prior to this discussion though, a few words need 
to be mentioned about the aetiology of LAO. 
 
The two most prevalent risk factors associated with the formation of LAO are 
extra- and intracranial atherosclerosis and atrial fibrillation.  
 
Atherosclerotic disease 
The relationship between atherosclerosis and LAO is as of today known to be 
due to artery-to-artery embolization, usually from the atherosclerotic arterial 
narrowing at the common carotid artery bifurcation. Another important 
mechanism is due to a combination of atherosclerotic stenosis and a 
superimposed propagating thrombosis leading to distal insufficiency of blood 
flow, hypoperfusion. Among the most well-recognized risk factors for ischaemic 
stroke are diabetes, hypertension and smoking. These three risk factors do not 
on their own account directly lead to LAO, however they facilitate the progress 
of atherosclerotic disease, thereby leading to LAO. We will here briefly describe 
the association between each of these risk factors and atherosclerosis. 
 
• Diabetes mellitus (DM)- The relative risk of stroke comparing diabetic 
with non-diabetic patients ranges between 2.3 – 6.8 in women and 1.4 – 
4.1 in men (273). Previous studies have shown both the increased 
prevalence of atherosclerosis in diabetic vs non-diabetic patients (274) as 
well as DM being an independent risk factor for both small and large 
vessel occlusive stroke (275) 
 
• Hypertension – The pathophysiological effects of hypertension lead to 
lipohyalinosis and subsequently to lacunar-type stroke, while the risk of 
LAO mainly is attributed to the acceleration of atherosclerosis 
development due to hypertension caused damage to the endothelium of 
vessels. Endothelial injury leads to plaque progression. In addition, 
chronic heightened intravascular pressure can cause vascular 
remodelling and stiffening which can lead to a reduced vascular lumen 
size. 
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• Smoking is a potent risk-factor for stroke, and previous studies have 
shown the aggravation of carotid artery atherosclerosis due to smoking 
(276, 277). The mechanisms behind increased atherosclerosis are 
numerous, including direct toxic effect of incomplete combustion 
products such as 1,3-butadiene on the endothelium, reduced levels of 
HDL-cholesterol and carboxyhaemoglobinemia (278). Nicotine in 
tobacco leads to impaired nitric oxide mediated vasodilation (279), while 
simultaneously promoting vasoconstriction by increasing the 
concentrations of the powerful vasoconstrictor endothelin (280). The 
effect is decreased cerebral perfusion.  
 
Atrial Fibrillation 
Atrial fibrillation is the most common cardiac arrhythmia (281). The association 
between atrial fibrillation and increased risk of thromboembolism and 
ischaemic stroke has been known for a long time, conferring a fivefold increased 
risk of ischaemic stroke (282). The atrial fibrillation associated strokes are caused 
by embolization of embolic material from the left atrium and left atrial 
appendage, and studies have shown the association of this condition with more 
severe ischaemic strokes than emboli from carotid artery disease, possibly due 
to embolization of larger particles in the case of atrial fibrillation (283). The 
underlying mechanisms facilitating thromboembolism in atrial fibrillation are 
complicated, and involve both abnormal changes in blood flow, vessel/atrial wall 
and blood constituents, leading to a hypercoagulable state in atrial fibrillation 
(284). 
 
Whether caused by atherosclerosis or cardiac embolization, occlusion of an 
intracranial artery finally leads to impaired blood flow and the ischaemic stroke 
is a fact, evidenced by neurological symptoms. The remainder of the 
introduction of this thesis will cover prediction and identification of patients 
with LAO based on baseline findings, of which stroke-severity is the most 
important. 
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1.11.1 Severity of stroke and cerebral large arterial occlusion 
When the stroke has become a clinical fact, evidenced by acute neurological 
symptoms, several studies have found an association between symptom severity 
and the presence of an arterial occlusion. The first study showing this direct 
relationship was the Emergency Management of Stroke Bridging Trial (EMS), 
comparing iv-tPA/IA with placebo/IA patients (58). A subsequent study by 
Derex et al investigated this association specifically, 54 acute ischaemic stroke 
patients being assessed with MRA in the hyper-acute phase. Each point of 
increase on the NIHSS conferred an odds ratio of 1.28 (95% CI 1.11-1.46) for the 
presence of an arterial occlusion. Further studies confirmed these findings (285, 
56). The arterial occlusions have been evidenced by either digital subtraction 
angiography or by CT/MR angiography (CTA/MRA) (286, 56, 285, 57, 58). These 
studies found varying optimal NIHSS cut-offs for predicting arterial occlusion, 
one study encompassing all occlusions when setting the NIHSS cut-off at 15 (58), 
another study detecting 80% of occlusions with NIHSS cut-off at 16 (57). One 
study found the best compromise of sensitivity and specificity for prediction of 
arterial occlusion at an NIHSS cut-off of 10 (285), another study showed a PPV 
of 91% at NIHSS cut-off 12 (56). Major limitations of these studies were relatively 
small cohort sizes, ranging from 35 (58) to 226 (56), as well as high average stroke 
severity (median and mean NIHSS around 14). The definition of arterial 
occlusion varied, some studies only including only proximal occlusions 
(terminal ICA, M1) while other studies included more distal occlusions (M2).  
A later study by Maas et al (54) enrolling 699 patients in a prospective cohort 
study involving CT angiographic imaging in acute stroke, found that although 
high NIHSS scores correlated with the presence of proximal arterial occlusions 
(LAO), no NIHSS score threshold could be applied without missing the majority 
of occlusive lesions (the authors concluded that a NIHSS cut-off³2 would be 
needed to identify 90% of proximal occlusions).  
 
These disparate findings lead to further investigation into the association 
between baseline NIHSS and arterial occlusion in acute ischaemic stroke. In a 
study published in Neurology 2011 (52), the validity of the NIHSS in predicting 
arterial occlusions (not only LAO) was found to be time-dependant, with 
increasing time from stroke onset to imaging resulting in a decreased predictive 
value and lower NIHSS threshold values. The association between NIHSS and 
arterial occlusion was investigated separately in patients presenting prior to or 
later than 6 h after stroke onset. Within 6h, the best cut-off was NIHSS 7 
(sensitivity 76% and specificity 70%) while the cut-off after 6h was 4 (sensitivity 
65% and specificity 62%). This time-dependence was subsequently confirmed in 
a later study by Heldner et al (51) investigating the relationship between baseline 
NIHSS and arterial occlusion, stratifying time from onset to clinical evaluation 
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as 0-3h, 3-6h and >6h. The optimal NIHSS cut-off for predicting LAO (ICA, 
M1/M2, intracranial vertebral artery and basilar artery) at 0-3 h was 9 (PPV 
80.7%)and at 3-6 h 7 (PPV 77%).  In posterior strokes, the association was poor 
irrespective of time elapsed between stroke and clinical evaluation.  
In project 1 of the current thesis, which is the largest study investigating this 
association, the same tendency was observed, the best NIHSS cut-off in general 
predicting arterial occlusion (without specification whether proximal or distal) 
being 11 (PPV 63.6%), but reducing to 10 at imaging time points past 2h after 
stroke onset (287). The time from symptom onset to evaluation clearly plays an 
important role regarding the ability of the NIHSS to predict the presence of 
arterial occlusions. 
 
1.11.2 Existing models for predicting large arterial occlusion 
Clear and strong associations between increasing baseline stroke severity 
measured by the NIHSS and presence of LAO open up for the possibility of 
predicting the likely presence of LAO already in the prehospital phase before 
vascular imaging is available. The recently updated Karolinska Stroke Update 
guidelines on mechanical thrombectomy in acute ischaemic stroke, supported 
by the European Stroke Organization amongst others, open up for the possibility 
of prehospital selection of patients with NIHSS³9 within 3h of symptom onset 
for transfer to centres with multimodal imaging and availability of 
thrombectomy (288). 
Although baseline stroke severity measured by the NIHSS score predicts the 
presence of LAO, the full NIHSS is time-consuming and probably too 
complicated in the prehospital setting. This has sparked the development of 
several simplified scales, aiming at predicting LAO in the prehospital stage based 
on assessment of only a few highly predictive parameters, mostly derived from 
the NIHSS. 
We will now discuss the available prediction models published so far, as the third 
project of this thesis investigates the value of various models based on 
simplifications of the NIHSS 
for predicting LAO. Table 5 summarizes the available scores. 
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 3-ISS LAMS RACE CPSSS PASS FAST-
ED 
VAN G-FAST 
LoC 0/1/2   0/1 0/1    
Gaze 0/1/2  0/1 0/2 0/1 0/2 0/1 0/1 
Facial 
motor  
 0/1 0/1/2   0/1  0/1 
Arm 
motor 
0/1/2 0/1/2 0/1/2 0/1 0/1 0/2 0/1 0/1 
Grip 
strength 
 0/1/2       
Leg 
motor 
  0/1/2      
Aphasia   0/1/2   0/2 0/1 0/1 
Neglect   0/1/2   0/2 0/1  
.  
Simple 3-item Stroke Scale (3-ISS) (286) - The 3-ISS is a prehospital LAO 
prediction algorithm, based on a prospectively collected cohort of 171 patients, 
83 of which underwent MRA. The 3-ISS is composed of modified versions of the 
NIHSS sub-items level of consciousness, gaze and motor function (composite of 
arm and leg function). These items were chosen from a clinical sense, not from 
a statistical analysis of best predictors. The score ranges 0-6. A high correlation 
between 3-ISS and NIHSS was seen. A score of ³4 predicted proximal vessel 
occlusion with an overall accuracy of 0.86 (sensitivity 67%, specificity 92%, 
positive predictive value 74% and negative predictive value 89%), compared to 
NIHSS³14 which had an overall accuracy of 0.93 (sensitivity 86%, specificity 95%, 
positive predictive value 86% and negative predictive value 95%). The scale has 
been externally validated, generally showing a poorer predictive value mainly 
due to a reduced sensitivity at the optimum cut-off (289, 290). 
 
Los Angeles Motor Scale (LAMS) (291) - The LAMS is a motor stroke deficit scale 
derived from the motor examination part of the broader stroke recognition 
instrument Los Angeles Prehospital Stroke Screen (LAPSS). The score consists 
of facial motor function, arm motor function and grip strength. The score ranges 
0-5. The LAMS has previously shown a high correlation with the NIHSS. In a 
retrospective analysis using two databases, one with patients enrolled in clinical 
randomised trials and one with patients entered into a stroke registry (GWTG), 
the association between LAMS and proximal arterial occlusion was assessed in 
119 <12h acute ischaemic stroke patients. Median NIHSS was 14, and 62% of the 
Table 5. Existing simple models based on NIHSS sub-items for predicting vessel occlusion. 
Numbers indicate available scoring option. LoC= Level of Consciousness, 3-ISS =3-item-
Stroke-Scale, LAMS = Los Angeles Motor Scale, RACE = Rapid Arterial Occlusion Evaluation 
scale, CPSSS = Cincinnati Prehospital Stroke Severity Score, PASS = Prehospital Acute Stroke 
Severity Scale, FAST-ED = Field Assessment Stroke Triage for Emergency Destination, VAN = 
Vision, Aphasia, Neglect Assessment, G-FAST = Gaze-Face-Arm-Speech-test. 
G-FAST= Gaze-Face-Arm-Speech test. 
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patients had arterial occlusions (58% ICA or M1 occlusions). Median LAMS score 
was 5 vs 2 in patients harbouring arterial occlusions vs no occlusions. LAMS 
predicted the presence of arterial occlusions well, AUC 0.85, and at the optimal 
cut-off  ³4, a sensitivity of 81% and a specificity of 89% were seen. The AUC for 
the full-item NIHSS was 0.933, optimum cut-off NIHSS³11 with overall accuracy 
0.89 (sensitivity 91%, specificity 87%). External validation has shown promising 
results, however poorer than that presented in the original study (AUC 0.74) 
(289) 
 
Rapid arterial occlusion evaluation scale (RACE) (292) - The RACE scale was 
developed on a retrospective cohort of 654 acute ischaemic stroke patients 
evaluated in the acute setting. Univariate analysis discovered the NIHSS sub-
items most closely associated with large arterial occlusions, and subsequent 
ROC-analysis was then performed to find the combination of items with highest 
AUC. The following sub-items were included in the score: facial motor function, 
arm motor function, leg motor function, gaze, agnosia (if left hemiparesis) and 
finally aphasia (i.e. LOC commands if right hemiparesis). The score ranges 0-9. 
The scale was subsequently validated by emergency medical technicians in the 
field, who scored patients upon first contact and then transferred them to a 
comprehensive stroke centre where NIHSS evaluation and imaging was 
performed. The validation was based on 357 patients. Strong associations 
between prehospital RACE scoring and arrival NIHSS were seen (Spearman 
correlation coefficient 0.76). Median NIHSS was 8. LAO was detected in 21.3% of 
patients. ROC analysis resulted in an AUC of 0.82 for detection of LAO, and 
slightly higher in the subgroup with anterior occlusions. The RACE cut-off ³5 
resulted in a sensitivity of 85%, specificity 68%, positive predictive value 42% 
and negative predictive value 94%. The full-item NIHSS predicted LAO with an 
AUC of 0.85. Best NIHSS cut-off ≥11was associated with a sensitivity of 88% and 
a specificity of 72%. The RACE score is the only LAO score so far prospectively 
evaluated in the prehospital setting. External validation has shown varying 
results, generally with a poorer sensitivity at the optimum cut-off (289, 293, 290). 
An RCT is currently recruiting patients in Spain, randomising acute stroke 
patients with RACE ³4 for either direct transfer to a tertiary centre with 
endovascular capabilities or to the nearest centre lacking endovascular 
capabilities. The main hypothesis is that direct transfer to a tertiary centre with 
endovascular capabilities will lead to an improved distribution of the 3-months 
mRS (ClinicalTrials.gov NCT02795962). 
 
Cincinnati Prehospital Stroke Severity Score (CPSSS) (294) - The CPSSS was 
developed using data from the two NINDS trials, and designed for predicting 
NIHSS≥15 (624 patients), and subsequently validated on IMS-III data (650 
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patients), where a secondary outcome was the presence of large arterial 
occlusions. In the derivation cohort, the individual NIH sub-items most 
predictive of severe stroke were chosen. The items most predictive of severe 
stroke were gaze, motor function (right arm, right leg and left leg) and language, 
for simplicity and ease of use in the prehospital setting the following parameters 
were chosen to be included in the score: gaze, arm motor function and level of 
consciousness commands and questions (replacing language function). The 
score ranges from 0-4, higher scores reflecting higher stroke severity. In the 
derivation cohort, AUC for detecting NIHSS≥15 was 0.89. The score was then 
validated in IMS-III patients, 303 patients with known vascular status. For LAO, 
CPSSS had an AUC of 0.67, scoring ≥2 resulted in an 83% sensitivity and a 40% 
specificity. External validation has shown varying results, generally with a poorer 
sensitivity at the optimum cut-off (289, 293, 290). 
 
Prehospital Acute Stroke Severity (PASS) scale (289) - The PASS scale was 
developed on a retrospective analysis of a Danish multicentre cohort of 3127 iv-
tPA and/or thrombectomy treated patients. Individual NIHSS sub-items most 
predictive of vascular occlusion (site not specified) were selected and the most 
optimum combination chosen. Pre-analysis, consensus on maximum 4 items 
was decided upon, excluding certain parameters such as facial palsy, ataxia, 
neglect etc. which were expected to be difficult to evaluate in the pre-hospital 
setting. The best model included items level of consciousness questions, gaze 
and arm motor function. The score ranges 0-3. The model was derived on 2/3 of 
the cohort, and validated in the remaining 1/3. Median NIHSS was 7 and 35% of 
the patients had occlusions. The model showed an AUC of 0.75 for detecting 
vessel occlusion in the derivation cohort (0.74 in the validation cohort) and the 
optimum cut-off ≥2 yielded a sensitivity and specificity of 64% and 83% 
respectively in the entire population. The previously published scores discussed 
above were validated in the same cohort showing similar performance. To our 
knowledge, the scale has not undergone validation prospectively in the 
prehospital setting. The scale has undergone external validation in SITS data 
with decent results (295). 
 
Field Assessment Stroke Triage for Emergency Destination (FAST-ED) (293) - 
The FAST-ED score was developed choosing items of the NIHSS with a higher 
predictive probability of LAO, and derived from NIHSS assessments performed 
by certified research personnel at hospital admission. The score consists of the 
NIHSS sub-items facial motor function, arm weakness, speech, gaze and neglect, 
ranging 0-9. The score was tested in 727 patients consecutively entered in a 
prospective cohort study at two university hospitals, in whom vascular imaging 
data were obtained. Median baseline NIHSS was 5, and LAO was detected in 33% 
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of patients. In patients undergoing vascular imaging within 6h, AUC of the score 
for predicting LAO was 0.83 (not significantly different from the full-item NIHSS 
but significantly better than RACE and CPSSS which were tested in the same 
cohort). At the optimum cut-off of ≥4, a sensitivity and specificity of 61% and 
89% respectively were seen. To our knowledge, the score has not undergone 
prospective validation, and the main limitations here would be complexity and 
inclusion of certain sub-items with poor reliability. 
 
Vision, Aphasia, Neglect (VAN) Assessment (296) - VAN was developed using 
clinical reasoning, including those parameters most likely to be associated with 
large arterial occlusion and cortical ischaemia. The model classes patients as 
either VAN positive or negative, after an initial screening for arm paresis. If no 
arm paresis is detected, the patients are classed as VAN negative. If paresis is 
present, further screening for any one of visual field defects/gaze, aphasia or 
neglect is performed. Presence of any one of these cortical symptoms classes the 
patient as VAN positive. In this study, stroke-research nurses were trained in the 
use of the model, and it was subsequently tested on 62 consecutive code stroke 
activations. No VAN-negative patient had an occlusion amenable to 
endovascular intervention, and all 14 patients going on to mechanical 
thrombectomy were VAN-positive. Sensitivity in this small pilot-study was 100%, 
specificity 90%, PPV 74% and NPV 100%. The results need to be interpreted with 
caution. The sample size was small, and applicability in a prehospital setting may 
not be equally favourable considering the rigorous training and preparation that 
study-members of the pilot-study went through, which may not be possible on 
a larger scale. The reliability of some of the included items (gaze) may entail 
problems in a larger-scale implementation, Nonetheless, the results of this small 
study are definitely interesting.  
 
Vanacker et al (297) - This Swiss group developed a LAO prediction model 
aiming at investigating whether other baseline parameters in addition to NIHSS 
would improve prediction. The model was developed on a cohort of 
consecutively enrolled patients (1645 patients) in the ASTRAL database with 
vascular imaging performed within 12 h of symptom onset, and subsequently 
validated in an independent cohort of 848 patients. Five predictors of LAO were 
found: admission NIHSS (1p per point), female gender(3p), hemineglect(5p), 
prestroke independence(3p) and atrial fibrillation(2p). The percentage of LAO 
in the derivation and validation cohorts was 21% and 28% respectively. The AUC 
in the pooled derivation and validation cohorts was 0.84, with an optimum cut-
off of the new score (based on an algorithm simultaneously maximising 
sensitivity and positive predictive value) at 16. At this cut-off, the sensitivity and 
specificity in the validation cohort was 84% and 71% respectively. Compared to 
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the NIHSS score alone (AUC 0.83), the new score performed significantly better, 
albeit with questionable clinical relevance. The authors therefore concluded 
that, although other baseline parameters may improve the predictive accuracy 
of a model based on the NIHSS alone, the gain in clinically meaningful 
improvement is negligible at the cost of increased complexity. Therefore, models 
based solely on the NIHSS are to be preferred. This study is interesting, the only 
one so far incorporating other elements than stroke severity into an LAO 
prediction model. The main drawback of this model is the complexity, requiring 
both a full NIHSS assessment in addition to other predictive parameters. 
 
Scheitz et al (295) - This latest publication from the SITS Investigators validated 
several of the above mentioned scores on SITS data, as well as performed novel 
investigations into the predictive value of the NIHSS profiles described by 
Sucharew et al (193) (see section 1.8). This retrospective study was based on 3505 
prospectively enrolled patients in the SITS database, with complete NIHSS data 
and vascular imaging. Median NIHSS of the entire cohort was 9, and large 
anterior vessel occlusion was detected in 23.6% of the population. One main 
finding was the graded relationship between all prehospital scores and the 
NIHSS symptom profiles with LAO, increasing scores in all models associated 
with higher odds ratios for LAO. In this analysis, the single item most predictive 
of occlusion was gaze, and addition of gaze to the items of the FAST-score, G-
FAST (gaze, facial motor function, arm motor function and speech), significantly 
improved the model (from AUC 0.645 to 0.722). The previously published 
prehospital scores, the new G-FAST model and the NIHSS profiles all showed 
similar predictions as the full NIHSS. The main conclusion of this article was not 
the superiority of any prehospital scale over another, rather the feasibility of 
using simplified scales rather than the full NIHSS, as the simplified scales 
performed similar to the NIHSS. The authors also pointed out how different cut-
offs of the scales may serve different purposes in various settings. In some 
situations, a high specificity cut-off may be desirable, in other cases a high-
sensitivity cut-off. These concepts will be discussed in the Discussion section of 
Study 3. 
 
In conclusion, several models for predicting the likelihood of patients 
harbouring a large vessel occlusion have been published, however only one to 
our knowledge has actually been validated in a prehospital setting (292). No 
globally agreed upon consensus on the optimum method for triage of acute 
stroke patients to Comprehensive Stroke Centres with endovascular capabilities 
exists. Part of the stroke community is sceptical towards prehospital triage based 
on stroke severity, arguing that any threshold, whether on the full NIHSS or a 
simplified score, will inevitably lead to either futile transfers or missed 
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opportunities for intervention (298).  The last word on LAO prediction has not 
yet been said, and the final project in this thesis will further investigate possible 
alternative strategies for identifying this highly important patient group. 
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2 AIMS 
 
The overall aim of this thesis was to investigate the association between 
symptom severity in the acute setting of ischaemic stroke and 
 
1) The presence of arterial occlusions and 
2) long-term functional outcome assessed with the mRS. 
 
In the final project, conceptually separated from the first 3 studies, we aimed to 
investigate a novel method for assessing 3-month mRS follow-up after acute 
stroke. 
 
Prediction of long-term functional outcome in the acute phase may help 
planning of resource allocation, may serve a role in treatment decisions and may 
allow for improved patient selection in randomised trials and control of cohort 
composition in non-randomised trials. To date, several predictive models have 
been proposed, however no one has yet gained any widespread use. Prediction 
of large arterial occlusions in acute ischaemic stroke, before vessel imaging has 
been performed, may have important implications on prehospital triage of 
patients likely harbouring large arterial occlusions potentially amenable to 
endovascular intervention. 
 
Routine assessment of long-term functional outcome after stroke is lacking in 
some settings, and methods for increasing the rate of follow-up are important, 
especially in circumstances with limited resources and infrastructure. 
 
Based on the above, the following hypotheses were formulated: 
 
Study 1:  
1) Threshold values on the baseline NIHSS predict the presence of arterial 
occlusions in the acute setting of stroke with a sufficient accuracy, and 
2) Threshold values on the baseline NIHSS predict long-term functional 
outcome after acute ischaemic stroke with a sufficient accuracy. 
 
Study 2: 
1) THE ASTRAL and DRAGON scores, two already available stroke 
prognostication models, predict long-term functional outcome with 
sufficient accuracy in the large SITS-ISTR cohort. 
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Study 3: 
1) NIHSS sub-items together with other clinical parameters predict the 
presence of large artery occlusions in patients with suspected acute stroke 
 
Study 4: 
1) A novel mobile phone-based self-assessment tool of mRS at 3 month after 
acute stroke is comparable to that in clinical assessments. 
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3 MATERIALS AND METHODS 
Study 1-3 of the present thesis are based on the Safe Implementation of 
Treatments in Stroke- International Stroke Treatment Register (SITS-ISTR, 
http://sitsinternational.org).  
I will therefore start by giving a short introduction to the background and 
rationale for this world-wide stroke treatment register. 
 
3.1 THE SITS INTERNATIONAL STROKE TREATMENTS REGISTER 
The SITS-ISTR is an international non-profit, internet-based, academic-driven 
global stroke treatments register, today containing data on close to 140 000 
patients from over 70 countries across the world. The SITS registry is 
coordinated from the Karolinska Stroke Research Unit and represented by the 
SITS Scientific Committee, SC. The SITS SC provides guidance for the various 
projects and activities taking place in the organization. Each participating 
country is represented by one or more National Coordinators, NC, responsible 
for the SITS-ISTR in the specific country. The NC coordinates and supports 
participating centres, oversees the regulatory and ethical requirements and has 
access to complete data from all national centres. Each centre is represented by 
a local coordinator, LC, an authorized stroke physician responsible for the 
hospitals stroke unit. Each individual centre owns its own data. 
The initiative for the register was sparked in 1996 by the European-Australian 
randomised stroke thrombolysis trial (ECASS) participants. The register gained 
a broader international role in 2002, when the EU license for intravenous 
alteplase in acute ischaemic stroke was approved under the condition that an 
observational safety study be initiated, SITS-MOST. SITS-MOST recruited 6843 
patients between 2002-2006, this pivotal observational study proving the safety 
of use of iv-tPA within 3h in acute ischaemic stroke (299). SITS-MOST data are 
embedded within the SITS-ISTR database. Approval for patient-enrolment is 
obtained in countries that require this; other countries approve the register for 
conduct as an anonymized audit. Patient data are entered electronically and 
encrypted in order to preserve patient integrity. Data withdrawals for 
researchers are provided with individual patients denoted by anonymized case-
control numbers according to the structure: [Nation and Centre code] [Date of 
initial data entry] [Number from 01 and up, in case of several patients being 
entered by the same centre on the same date].  
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3.2 STUDY SUBJECTS 
 
3.2.1 Study 1 
All patients registered in the SITS-ISTR between December 2002 and March 2013 
were considered. In total, 57 213 ischaemic stroke patients with iv-tPA treatment, 
treated within and outside license criteria, were recorded in SITS-ISTR at 793 
centres from 44 countries of whom 94.6% were from Europe. Mean age was 68.2 
years, 56.4% men, and median baseline NIHSS score 11. From the entire cohort, 
data on three-months mRS were available in 44 331 patients (77·5%), and data on 
baseline vessel occlusions were available in 11 632 patients (20·3%). Exact 
localization of vessel occlusions was not available, merely the presence/absence 
of arterial occlusions was stated. Only patients with complete data for all 
included variables were included in the multivariate models. 
 
3.2.2 Study 2 
The same cohort and data-file as in study 1 was used for this study, with the same 
recruitment period and the same number of patients. Only patients with 
complete mRS outcome data and with complete data for the ASTRAL and 
DRAGON scores respectively were entered into the study. A total of 36131 iv-tPA-
treated patients with complete data for the ASTRAL score and 33716 iv-tPA-
treated patients with complete data for the DRAGON score were included in the 
respective analyses.  
3.2.3 Study 3 
The study was based on patients registered in the Safe Implementation of 
Treatments in Stroke (SITS)- International Stroke Treatment Register (SITS-
ISTR) between December 1st 2012 and October 23rd 2015. Only patients with 
available CT angiography/MR angiography (CTA/MRA) and baseline NIHSS 
data treated with iv alteplase and/or endovascular thrombectomy were 
considered. The time period was chosen based on the time of implementation in 
the database of additional variables for registering detailed information on 
arterial occlusion site using baseline CTA/MRA. Data for this study were 
contributed by hospitals which reported specified arterial occlusion sites in at 
least 20 patients in whom any occlusion was reported as present. This selection 
of experienced centres was done in order to ensure a high-quality registration of 
arterial occlusion data. Between 1st December 2012 and 23rd October 2015, 5573 
patients with available CTA/MRA data from large-volume centres were 
registered in the database. After selecting patients with specified anterior 
circulation occlusion site and clinically defined as anterior circulation strokes in 
cases of no visible occlusion, 4011 patients remained. Baseline NIHSS (and 
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complete NIHSS sub-item data) was available in 97% of the study group 
(3897/4011).  Of these, 1896 patients (49%) had a large arterial occlusion, while 
2001 patients (51%) had either no occlusion or more distal occlusions. 
 
3.2.4 Study 4 
Acute stroke patients (ICD code I61=haemorrhagic and I63=ischaemic) admitted 
to the Stroke unit at the Karolinska University Hospital– Solna during the period 
March to May 2014 were consecutively offered participation in the study, 
regardless of acute interventions or stroke severity. All acute stroke patients 
were screened during regular working hours (08.00–17.00) and informed about 
the study and offered participation. The following inclusion criteria were used:  
1. Clinical signs and symptoms concurring with a diagnosis of acute stroke.  
2. The patient and/or a close relative/caregiver had an available compatible mobile 
phone.  
3. The patient received an ICD diagnosis of either I.61 (haemorrhagic) or I.63 
(ischaemic) at discharge.  
The following exclusion criteria were used:  
1. Clinical signs and symptoms concurring with a diagnosis of transient ischaemic 
attack.  
2. Neither the patient nor a close relative/caregiver had an available compatible 
mobile phone.  
During the study period, 74 patients fulfilled study inclusion criteria. 12 patients 
declined participation and 11 patients dropped out after inclusion for personal 
reasons. 3 included patients died. 48 patients completed the entire study, 
completing both outcome assessments. The mean age of the final 48 patients 
completing the study was 67 years, 37.5% were female, median baseline NIHSS 
score was 5 (interquartile range [IQR] 2–10.5, range 0–23), and 12.5% patients had 
a haemorrhagic stroke. 
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3.3 STUDY DESIGN 
 
3.3.1 Studies 1-3 
The first 3 studies which are based on SITS data are observational. In all iv-
tPA/thrombectomy-treated patients in SITS, data was collected at 0 h (baseline), 
2 h, 24 h and 7 days post-treatment. Brain imaging (CT and/or MRI) performed 
at baseline and at 22-36 h was required in all patients. Additional imaging, such 
as CT/MR-angiography, was optional and could be added if available. Functional 
evaluation using the mRS was performed at 3 months. Figure 25 gives an 
overview over the standard time points of data gathering and outcome 
assessment in SITS-ISTR. 
 
 
Figure 25. Overview of the time-line for data gathering in SITS-ISTR. Rx denotes the acute 
intervention (iv-tPA and/or thrombectomy). 
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3.3.2 Study 4 
 
A flow chart depicting the process of selecting the final study cohort is shown in 
Figure 26. Acute stroke patients were consecutively offered participation in the 
study. If included, the mobile phone application (MA) was installed on the 
patient’s personal mobile phones. In cases where the patients could not 
participate themselves, we included a close relative/caregiver who would answer 
in the patient’s place. All study participants were equipped with an instruction 
sheet containing detailed instructions on how to answer the mobile phone based 
mRS questionnaire. During the follow-up period, the study participants were 
reminded about participation in the study through automatic monthly messages 
in MA. No instructions were given regarding the questions to be answered in the 
 
Figure 26. Flow chart of patient inclusion in study 4. Reproduced from Cooray et al, Circulation: 
Cardiovascular quality and outcomes 2015 (138). Permission for use not required. 
		 77	
MA, apart from the written instructions sheet. Within a week after answering 
the questionnaire, a blinded mRS-certified study personnel rated the patients 
with a clinical visit mRS assessment. This assessment was performed in 2 parts. 
The first part consisted of a conventional unstructured interview followed by a 
second part, where the RFA questionnaire was used in a standard structured 
manner. An overall assessment of the interview taking into account both parts 
of the interview was done, and the patients assigned an mRS score by the first 
rater. The entire interview was filmed and subsequently judged by a second 
blinded study personnel. The second rater, however, also rated the 2 parts of the 
interview separately, generating scores for the 2 parts of the interview separately 
in addition to an overall interview score. In cases where the first 2 raters ranked 
the patient differently on the overall interview, a 3rd rater viewed the footage, 
and in collaboration with the first 2 raters assigned a final score. Participants’ 
mobile phone–based questionnaire responses were translated to an mRS score 
using a predefined protocol. In cases where both patient and relative/caregiver 
sent in MA responses and 2 different mRS scores were obtained for a certain 
patient, patient scores were used in the subsequent statistical analysis. During 
the study period, no technical problems were reported, and responses from the 
study participants were received smoothly after encryption and stored securely. 
The mobile phone questionnaire responses were first opened after final 
adjudication of the clinical visit assessment score. 
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3.4 DATABASE VARIABLES IN SITS 
With a few exceptions, most qualitative data were entered in a binary form, 
registering presence/absence of the variable in question. Ordinal or continuous 
variables were entered as their respective numerical value. An option for 
entering “unknown” distinct from “missing” was possible. Demographic 
characteristics included gender, age, country of origin and centre-code. Past 
medical history included hypertension, atrial fibrillation, congestive heart 
failure, hyperlipidemia, smoking (current or previous), history of previous stroke 
and pre-stroke functional status as measured by the mRS. Current medication 
at stroke-onset included antihypertensive treatment, aspirin, dipyridamole, 
clopidogrel, any other antiplatelet, statins and anticoagulants. Time-points 
recorded were time of stroke onset, time to admission, time to imaging, time to 
treatment with related time-intervals. Laboratory values included blood glucose 
prior to treatment and serum cholesterol. Thrombolysis-specific data included 
patient’s weight and dose of alteplase. Treatments during the hospital stay, 
including antiplatelet therapy, anticoagulants and antihypertensive 
medications, were registered at discharge. NIHSS (with complete breakdown 
into sub-items) were registered at admittance, 2h, 24h and 7 days. Systolic and 
diastolic blood pressure was recorded at the same time-points. 
CT and/or MRI at baseline and 22-36 h post-treatment was mandatory, and 
recorded imaging variables at baseline included information on the 
presence/absence of dense-vessel sign and early infarct signs. At 22-36 h, 
presence/absence of the dense vessel sign, early infarct changes, intracerebral 
haemorrhage and cerebral oedema were registered. Optional imaging findings 
such as CT/MR-angiography was possible to register. Up until December 2012, 
only a simple option ticking in the presence or absence of a vascular occlusion, 
without information on vascular occlusion site, was available. In December 2012, 
additional variables for registering detailed information on arterial occlusion site 
using baseline CTA/MRA were implemented. 
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3.5 OUTCOME VARIABLES 
 
3.5.1 Study 1 
The outcomes were functional independency at three-months measured by mRS 
scores 0–2 and presence of baseline vessel occlusion diagnosed with CT/MR 
angiography (registered as presence/absence of arterial occlusion, site not 
specified). All assessments of imaging studies and neurological status were done 
according to clinical routine at centres participating in the SITS-ISTR. All 
imaging scans and vessel occlusions on CT/MR angiography were evaluated 
locally.  
3.5.2 Study 2 
Functional dependency and death at 3 months measured by mRS scores of 3 to 
6 was the main outcome used in the development of both the ASTRAL and 
DRAGON scores. 
3.5.3 Study 3  
Main outcome was presence of an anterior circulation large arterial occlusion. 
Arterial occlusion was defined as a complete occlusion or less than 50% filling of 
the affected vascular territory on CTA/MRA. LAO in the anterior circulation was 
defined as occlusion of any segment of the internal carotid artery, carotid 
terminus or the M1 branch of the middle cerebral artery. Patients harbouring 
posterior circulation occlusions were not included in the analysis. In cases where 
more than one arterial segment was reported as being occluded, the most 
proximal vessel was registered for the analysis. The control population was 
defined as patients with no occlusions or with more distal occlusions. In order 
to ensure that patients registered as having no occlusions were clinically 
suffering from anterior circulation infarction, only patients specifically 
registered as suffering from an anterior circulation syndrome were included in 
the analysis. All assessments of imaging studies were done according to clinical 
routine at centres participating in the SITS-ISTR, and no central assessment of 
imaging data was performed. 
3.5.4 Study 4  
The main outcome measure was the 3 month mRS score, comparing the overall 
clinical assessment of the mRS with the mRS derived from the mobile phone-
questionnaire. In cases where both patient and caregiver answered the mobile 
phone questionnaire, patient answers were used in the main outcome analysis. 
Secondary outcomes included comparison of the mRS score derived from the 
clinical structured-interview with the mRS derived from the mobile phone-
questionnaire. 
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3.6 STATISTICS 
 
3.6.1 Study 1-3 
Descriptive statistics for baseline, demographic, and imaging data were 
performed, comparing groups of patients in accordance with the purposes of 
each respective study. Proportions were calculated for categorical variables, 
dividing the number of events with the total number excluding 
missing/unknown cases. Medians were calculated for continuous variables. For 
calculation of statistically significant differences between proportions, we used 
the χ2 method, for medians, we used the Mann–Whitney U-test, and for means 
we used the Student t-test. To adjust for baseline differences between the various 
comparator groups in the three first studies, multivariate binary logistic 
regression was subsequently performed. In all three studies, area under the curve 
(AUC) using Receiver Operating Characteristics (ROC) analysis were used to 
assess the discriminative performance of predictive models. Sensitivities, 
specificities, positive predictive values, negative predictive values and likelihood 
ratios were given where relevant. In study 2, calibration was assessed by plotting 
observed outcome against predicted outcome. In study 3, for each model we 
assessed the sensitivity and specificity for LAO at three different cut points: at 
an optimal cut-point maximising the Youden index, at a cut-point maximising 
the specificity (as close to 80% as possible) and at a cut-point maximising the 
sensitivity (as close to 80% as possible). In study 1, statistical analysis was 
performed in IBM SPSS Statistics 15.0 â, and in studies 2 and 3 Stata 14.1â was 
used. 
 
3.6.2 Study 4 
The main outcome measure was the weighted kappa score (quadratic). 
Unweighted kappa scores were also calculated. In addition, unweighted kappa 
scores were calculated for various dichotomizations of the mRS. Following 
standard convention, a kappa of 0 to 0.2 was considered poor, 0.21 to 0.4 fair, 
0.41 to 0.6 moderate, 0.61 to 0.8 good, and 0.81 to 1.00 excellent. Percentage 
agreement was calculated as well. All responses from study participants were 
compared with the overall clinical visit mRS assessment, as well as with the 
structured assessments separately. We also performed analysis for discrepancies 
between the first and second ratings.  
Statistical analysis was performed in IBM SPSS Statistics 15.0 â,  and Medcalcâ 
statistical software.  
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4 RESULTS 
 
4.1 STUDY 1 
In this study, 57 213 patients treated with iv-tPA from 793 centres in 44 countries 
recorded in the database were considered, 94·6% from Europe. Mean age was 68 
years, median baseline NIHSS score 11 and 56.4% men. Data on baseline vessel 
occlusions were available in 20% of the patients (11 632 patients) and 3-months 
mRS data were available in 78% of patients (44 331 patients).  
The calculated area under the curve (AUC) for predicting functional 
independency (mRS 0-2) from baseline NIHSS score was 0.775. The optimal cut-
off value for baseline NIHSS was estimated at 12 (73.4% specificity, 69.4% 
sensitivity, 75.0% NPV and 67.7 % PPV). ROC analysis on the anterior sub-cohort 
resulted in an area under the curve of 0.78 (specificity 73.16% and sensitivity 
70.96 %). ROC analysis in the posterior subcohort resulted in an AUC of 0.734 
(specificity 80.15% and sensitivity 53.80%). In Figure 27, adjusted odds ratios 
(aOR) for functional independency are shown as a function of baseline NIHSS 
scores. With increasing baseline NIHSS, aORs for functional independency 
decreased. The aOR for functional independency was 0.07 (CI 95% 0.05–0.11) at 
NIHSS score 12 when compared with NIHSS 0.  
The calculated AUC for prediction of baseline vessel occlusion from baseline 
NIHSS score was 0.678. The optimal cut-off value for baseline NIHSS was 11 
 
Figure 27. Odds ratios for functional independency, multivariately adjusted with 95% 
confidence intervals (vertical bars). Reproduced from Cooray et al, 2015 (287). Permission for use 
not required. 
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(64.4% specificity, 64.5 % sensitivity, NPV 65.3% and PPV 63.6%). Adjusted ORs 
for baseline vessel occlusion for the spectrum of baseline NIHSS scores are 
shown Figure 28. With increasing baseline NIHSS scores, aORs for baseline 
arterial occlusions increased. Comparing patients with NIHSS score 11 with 
NIHSS score 0, a 3.3 times increased risk of baseline occlusion was seen.  
The patients with arterial occlusions had significantly lower rates of functional 
independency as compared to the patients without, independently of the NIHSS 
score. Considering patients with an NIHSS >12, the presence of a vessel occlusion 
led to an approximately 40% lesser chance of functional independency at 3-
months compared to non-occluded patients. These results held strong after 
multivariate adjustment. Figure 29 shows the aORs for functional independency 
at 3-months between patients with and without vessel occlusion as per baseline 
NIHSS strata. 
 
 
Figure 28. Odds ratios for baseline vessel occlusion, multivariately adjusted with 95% 
confidence intervals (vertical bars). Reproduced from Cooray et al, 2015 (287). Permission for use 
not required. 
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The final important finding in the first study was the time-dependence of NIHSS 
thresholds for predicting both vessel occlusion and 3-months functional 
outcome. Comparing the cut-offs in patients undergoing imaging within 2-3 
hours after symptom onset with subjects scanned within the 1st hour, thresholds 
were 1p lower for functional independency and 2p lower for vessel occlusion in 
the later time-windows, see Table 6 (300).  
Onset to Scan time 
(min) 
Baseline NIHSS cut-off for 3-m 
functional independency 
(number of patients) 
Baseline NIHSS cut-off for 
baseline occlusion 
(number of patients) 
0-60 12 (6574) 12 (1732) 
61-120 12 (23225) 11 (5784) 
121-180 11 (10931) 10 (2756) 
181-270 9 (2607) 10 (838) 
Table 6. Variations in baseline NIHSS thresholds for three-month functional independency and 
baseline occlusion and median NIHSS for patients withand without vessel occlusions depending on 
time from stroke onset to imaging. Reproduced from Cooray et al, 2015 (287). Permission for use 
not required. 
 
 
 
 
 
 
Figure 29. Odds ratio for functional independency, comparison between patients with and 
without baseline occlusion for different NIHSS strata (reference group patients without 
occlusions). Multivariately adjusted with 95% confidence intervals (vertical bars). NIHSS, 
National Institutes of Health Stroke Scale. Reproduced from Cooray et al, 2015 (287). Permission 
for use not required. 
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4.2 STUDY 2 
A total of 36131 iv-tPA-treated patients with complete data for the ASTRAL score 
and 33716 iv-tPA-treated patients with complete data for the DRAGON score 
form the base for this study. Only patients with complete data for the respective 
score, with complete outcome data, and fulfilling the original inclusion criteria 
for the respective score cohort were included.  
ASTRAL 
The mean age (68 vs. 68 years), the proportion of female patients (42% vs. 43%) 
and the mean baseline glucose (7.1 vs. 7.1. mmol/L) were similar between the 
SITS and the ASTRAL cohorts. The mean stroke severity in the SITS-ISTR cohort 
was NIHSS 12 compared to 9 in the ASTRAL cohort. The onset-to-arrival time on 
average was lower (82.2 versus 395.8 minutes) in the SITS-ISTR cohort compared 
to the ASTRAL cohort. The AUC-receiver operating characteristic value for 
functionally dependent outcome (mRS 3–6) of the ASTRAL score on the SITS-
ISTR cohort was 0.790 (95% CI 0.786–0.795). A calibration plot comparing 
predicted vs observed percentage functional dependence (mRS 3-6) is seen in 
Figure 30. The largest discrepancy between the observed and the predicted 
proportion of functional dependency, over the entire range of score points, was 
acceptable at 11%, i.e. the maximum vertical distance between the predicted 
outcome line and the actual outcome line. ASTRAL underestimated the 
proportion of functional dependency in scores <40, and overestimated the 
proportion of functional dependency in scores >40. With increasing score cut-
offs on the ASTRAL score, an increasing likelihood ratio for functional 
dependency is seen.      
 
Figure 30. Calibration 
plot displaying the 
observed proportion of 
functionally dependent 
patients in SITS (dots) 
with 95% CI (vertical 
lines) as a function of 
the ASTRAL score; the 
green curve shows the 
predicted outcome 
according to the 
ASTRAL score, the 
yellow curve shows the 
best fitting logistic 
model depicting the 
actual observed 
outcome in the SITS 
cohort. Reproduced 
from Cooray et al, 2016 
(251). Permission for use 
not required. 
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DRAGON 
The median age was 70 vs. 69, the proportion of female patients 43% vs. 45%, 
and the median baseline blood glucose 6.5 vs. 6.6 mmol/L in the SITS-ISTR 
population compared to the DRAGON derivation cohort. Median stroke severity 
in the SITS cohort was NIHSS 12 compared to 9 in the DRAGON cohort. The 
proportion of patients with a dense vessel sign on first non- contrast CT scan 
was only marginally different between the 2 groups (19.9% vs 17.7% in SITS and 
DRAGON cohorts respectively). However, proportions of early infarct signs 
differed more significantly (16.5% in the SITS cohort versus 30.6% in the 
DRAGON cohort).  
The AUC-receiver operating characteristic value for functionally dependent 
outcome (mRS 3–6) of the DRAGON score on the SITS-ISTR cohort was 0.77 
(95% CI 0.769–0.779). A calibration plot comparing predicted vs observed 
percentage functional dependence (mRS 3-6) is seen in Figure 31. The largest 
discrepancy between the observed and the predicted proportion of functional 
dependency, over the entire range of score points was close to 17%. The 
DRAGON score generally overestimated the proportion of functional 
dependency.  
 
Figure 31. Calibration 
plot displaying the 
observed proportion of 
functionally dependent 
patients in SITS (dots) 
with 95% CI (vertical 
lines) as a function of 
the ASTRAL score; the 
green curve shows the 
predicted outcome 
according to the 
ASTRAL score, and the 
yellow curve shows the 
best fitting logistic 
model depicting the 
actual observed 
outcome in the SITS 
cohort. Reproduced 
from Cooray et al, 2016 
(251). Permission for use 
not required. 
 
With increasing DRAGON score cut-offs, decreasing positive likelihood ratios 
for functional independency are seen (data given in original article).  
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4.3 STUDY 3 
A total of 5573 patients with available CTA/MRA data from large-volume centres 
were extracted from the database, registered between 1st December 2012 and 
23rd October 2015. After selecting patients with specified anterior circulation 
occlusion site and clinically defined as anterior circulation strokes in cases of no 
visible occlusion, 4011 patients remained. Baseline NIHSS was available in 97% 
of the study group (3897/4011).  Of these, 1896 patients (49%) had a LAO, 2001 
patients (51%) had either no occlusion or more distal occlusions. Patients with 
and without LAO differed regarding several baseline variables, however not to 
any larger extent although being statistically significant. The most notable 
difference between LAO and non-LAO patients was in the total baseline NIHSS 
score at 16 versus 8 respectively. Higher systolic blood pressures were seen in 
non-LAO patients as well as a higher prevalence of atrial fibrillation in LAO 
patients.  
 
Table 7 shows the most predictive models with increasing number of included 
sub-items.  
 
Table 7. Sensitivity and specificity for predicting LAO for various models at optimum cut-off, high 
specificity cut-off and high sensitivity cut-off. Numbers in parenthesis are multivariately adjusted 
values, adjusting for baseline systolic blood pressure, prestroke modified Rankin Score, previous 
stroke and baseline treatment with Aspirin. For the 1-item model including sub-item 5, arm 
function, we have in italics given the respective sub-item cut-off for the three sensitivity/specificity 
scenarios.  NIHSS item 2 = gaze; NIHSS item 3 = visual fields; NIHSS item 4 = facial motor function; 
NIHSS item 5 = arm motor function; NIHSS item 6= leg motor function. 
 
Four predictors other than NIHSS score remained significantly associated with 
the outcome in the multivariate models and were thus adjusted for, the numbers 
Model  Optimum Youden cut-
off 
High specificity cut-off High sensitivity cut-off 
 AUC 
(adjusted) 
Sens 
(adjusted) 
Spec 
(adjusted) 
Sens 
(adjusted) 
Spec 
(adjusted) 
Sens 
(adjusted) 
Spec 
(adjusted) 
NIH item 5 0.72(0.74) 69(68) 
(NIHSS 5 ≥ 
3) 
70(72) 
(NIHSS 5 ≥ 
3) 
55(55) 
(NIHSS 5 = 
4) 
79(80) 
(NIHSS 5 = 
4) 
79(81) 
(NIHSS 5 ≥ 
2) 
55(53) 
(NIHSS 5 
≥ 2) 
NIHSS item 5 + 
NIHSS item 2 
0.75 
(0.76) 
70(72) 71(71) 64(59) 76(80) 78(80) 61(58) 
NIHSS item 5 + 
NIHSS item 2 + 
NIHSS item 4 
0.76(0.76) 68(70) 74(73) 60(61) 80(80) 81(80) 57(59) 
NIHSS item 5 + 
NIHSS item 2 + 
NIHSS item 4 + 
NIHSS item 3 
0.76(0.77) 65(72) 77(72) 57(61) 82(80) 80(81) 59(59) 
Full-item NIHSS 0.78 
(0.78) 
72(74) 72(72) 62(64) 80(80) 81(80) 59(60) 
Total NIHSS score 0.76 
(0.77) 
67(73) 75(70) 57(61) 81(80) 79(79) 60(59) 
NIHSS item 5 + 
NIHSS item 6 
0.73(0.75) 68(67) 72(73) 58(58) 79(80) 80(81) 53(53) 
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given in parentheses. These additional predictors were: baseline systolic blood 
pressure, pre-stroke modified Rankin Score, previous stroke and baseline 
treatment with Aspirin.  
 
The 1-item model associated with the highest AUC (0.720) included solely NIHSS 
sub-item 5, arm motor function. The optimum Youden cut-off (NIHSS item 5 ≥ 
3) resulted in a sensitivity and specificity of 69% and 70% respectively, patients 
above the cut-point presenting with median NIHSS 17 (IQR 14-21) and below the 
cut-point presenting with median NIHSS 7 (IQR 5-10). At the high-specificity 
cut-off (NIHSS item 5= 4) a sensitivity and specificity of 55% and 79% 
respectively was seen, patients above the cut-point presenting with median 
NIHSS 18 (IQR 15-21) and below the cut-point presenting with median NIHSS 8 
(IQR 5-12). The high sensitivity cut-off (NIHSS item 5 ≥ 2) resulted in a sensitivity 
and specificity of 79% and 55% respectively, patients above the cut-point 
presenting with median NIHSS 16 (IQR 12-20) and below the cut-point 
presenting with median NIHSS 6 (IQR 4-8). The full-item model resulted in an 
AUC of 0.775. The optimum Youden cut-off yielded a sensitivity and specificity 
of 72% and 72%, at the high-specificity cut-off a sensitivity and specificity of 62% 
and 80% was seen, and the high sensitivity cut-off resulted in a sensitivity and 
specificity of 81% and 59%. Figure 32 shows the area under the curve for LAO 
comparing the most predictive 1-item, 4-item and full-item models. 
   
 
Figure 32. Area under the curve (AUC) for predicting LAO, comparing the most predictive 
NIHSS 1-item, 4-items and full-items models. The 1-item model included NIHSS sub-item 5 (arm 
function), the 4-item model included sub-items 2, 3, 4 and 5 (gaze, visual fields, facial and arm 
motor function. The full-item model included all NIHSS sub-items. 
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4.4 STUDY 4 
The mean age of the 48 patients completing the study was 67 years, 37.5% were 
female, median baseline NIHSS score 5 (interquartile range [IQR] 2–10.5, range 
0–23). A total of 12.5% patients had a haemorrhagic stroke. Among the patients 
lost to follow-up (dropouts because of personal reasons), the mean age was 69, 
63.6% were female, median baseline NIHSS score was 4 (IQR 3–7.5, range 1–14), 
and 1 patient had a haemorrhagic stroke. The mean follow-up-time was 90.2 days 
(SD 3.9 days).  
Table 8 shows a summary of the agreement between clinical mRS assessment 
and MA mRS assessment for the overall and structured assessments, 
respectively.  
 
Table 8. Overall and structured assessment vs Mobile phone application (MA). Reproduced from 
Cooray et al, 2016 (138). Permission for use not required. 
 
 
 
 
 Overall clinical assessment vs MA Structured assessment vs MA 
Percentage 
agreement 
Weighted 
kappa 
Unweighted 
kappa 
Percentage 
agreement 
Weighted 
kappa 
Unweighted 
kappa 
Entire 
range of 
scores     
(0-5) 
excluding 
dead 
patients 
62.5% 0.89 
(0.82-
0.96) 
0.53 (0.36-
0.70) 
64.6% 0.89 
(0.82-
0.96) 
0.56 (0.39-
0.72) 
Entire 
range of 
scores    
(0-6) 
including 
dead 
patients 
64.7% 0.92 
(0.86-
0.97) 
0.57 (0.41-
0.73) 
66.7% 0.92 
(0.87-
0.97) 
0.59 (0.44-
0.75) 
mRS 0-2   
vs 3-5 
83.3% ------- 0.66 (0.45-
0.87) 
87.5% ------- 0.74 (0.56-
0.93) 
Patient    
vs MA 
72.7% 0.82 
(0.70-
0.94) 
0.59 (0.33-
0.85) 
72.7% 0.81 
(0.67-
0.95) 
0.58 (0.32-
0.85) 
Caregiver 
vs MA 
59.4% 0.86 
(0.76-
0.96) 
0.51 (0.30-
0.71) 
62.5% 0.87 
(0.77-
0.96) 
0.55 (0.35-
0.75) 
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In 30/48 patients, the mRS scores concurred perfectly (total agreement 62.5%). 
Of the remaining 18 patients, scores differed by 1 level in 16 patients and by 2 
levels in 2 patients. The weighted kappa was 0.89 (95% CI 0.82–0.96), and the 
unweighted kappa was 0.53 (95% CI 0.36–0.70). Results were similar comparing 
the structured RFA judgement with the MA mRS assessment. Percentage 
agreement dichotomizing independent from dependent functional level (mRS 
0–2 versus 3–5) was 83.3%, and the unweighted kappa score was 0.66 (0.45 to 
0.87). In table 9, a cross-tabulation summarizes the percentage agreement and 
unweighted kappa for all possible dichotomizations.   
 Clinician assessment score (mRS) 
 0 1 2 3 4 5 
Mobile 
phone based 
assessment- 
Score (mRS) 
0 2 1     
1 1 9 2    
2  2 7 2   
3  2 4 4 1  
4    1 2 1 
5     1 6 
Table 9. Cross tabulation of paired ratings. Reproduced from Cooray et al, 2016 (138). Permission 
for use not required. 
 
The percentage agreement between the 2 raters´ was 79% (38/48; the maximum 
disagreement was 1 score level), weighted kappa 0.95 (95% CI 0.92–0.99), and 
unweighted kappa 0.74 (95% CI 0.59–0.88).  
 
 
 
 
 
 
 
 
 
 
 
 
		90	
5 DISCUSSION 
 
5.1 STUDY 1 
There is a well-established association between baseline stroke severity 
measured on the NIHSS and arterial occlusions in the acute setting of ischaemic 
stroke (58, 285, 56). Likewise, the predictive value of the NIHSS in predicting 
long-term functional outcome after acute ischaemic stroke is firmly established 
(145, 139, 185, 186, 161, 187, 188). Although several studies have reported NIHSS 
thresholds for predicting baseline vessel occlusion, a large heterogeneity in the 
presented thresholds is seen. Moreover, studies examining specific NIHSS 
thresholds for predicting long-term functional outcome in iv-tPA treated 
patients are scarce. Most importantly, to our knowledge, no study so far has 
simultaneously studied and presented thresholds for predicting both the 
presence of arterial occlusions as well as poor long-term functional outcome. 
The major findings from this study were that NIHSS thresholds predicted the 
presence of arterial occlusions and long-term functional outcome with a fair and 
moderate discrimination respectively. NIHSS thresholds of 11 (AUC 0.68) and 12 
(AUC 0.78) were optimum for predicting the presence of arterial occlusions and 
long-term functional dependency in this study material. These optimum 
thresholds were derived using ROC-analysis, and further strengthened by odds 
ratio calculations derived after multivariate adjustment. Comparing patients 
with NIHSS=12 and NIHSS=0, a 10-fold reduction in the chance of a favourable 
outcome (mRS 0-2) was seen in patients with NIHSS 12.  Comparing patients 
with a NIHSS 11 and NIHSS 0, a 3-fold increase in the risk of an arterial occlusion 
was seen in patients with NIHSS 11. 
 
NIHSS thresholds for predicting the presence of cerebral arterial occlusions have 
been presented previously. These studies found varying optimal NIHSS cut-offs 
for predicting cerebral arterial occlusion, one study encompassing all arterial 
occlusions when setting the NIHSS cut-off at 15 (58), another study detecting 
80% of occlusions with an NIHSS cut-off at 16 (57). One study found the best 
compromise of sensitivity and specificity for prediction of any arterial occlusion 
at an NIHSS cut-off of 10 (285), another study showed a PPV of 91% at NIHSS 
cut-off 12(56). Important limitations of these studies were relatively small sample 
sizes, ranging from 35 (58) to 226 (56), as well as a high average stroke severity 
(median and mean NIHSS around 14). Our study is the largest study so far 
obtaining NIHSS thresholds for predicting arterial occlusions, and our median 
NIHSS was lower than that of several previous studies which included more 
selected patient populations. To our knowledge, only one previous study is based 
on a comparatively large cohort (n = 1603), presenting a favourable predictive 
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value of the NIHSS (baseline NIHSS>9 predicting arterial occlusion in the 
anterior circulation within 3-hours after symptom onset with a PPV of 86.4%) 
(51). Our study found a lower predictive value (baseline NIHSS>11 predicting 
arterial occlusion within 3-hours after symptom onset with a PPV of 63.9 %), 
possibly explained by our inability of separating distal from proximal occlusions. 
Few studies have specifically examined NIHSS threshold values for predicting 
functional outcome in patients with acute stroke, presenting optimum cut-offs 
for predicting long-term unfavourable functional outcome at NIHSS scores of 13, 
15 and 17 (145, 194, 195). Importantly, patients in these studies were not treated 
with iv-tPA. Regarding iv-tPA treated patients, one smaller study (108 patients) 
did not find a good predictive value (AUC 0·634) of the baseline NIHSS in 
predicting poor functional outcome (196). Patients in that study had a higher 
stroke severity (median NIHSS 17), and excluded patients with NIHSS ≤ 7 as well 
as absence of occlusion on MR angiography. Our results are more representative 
of the average stroke thrombolysis patient examined in the acute setting. 
Regarding ORs for 3-months favourable outcome (mRS 0-2) in specified NIHSS 
strata, patients with arterial occlusions in general had poorer outcome compared 
to patients without, irrespective of NIH strata. Comparing the occluded with the 
non-occluded patients in NIHSS strata 13-16, a more than 40% reduction in 
functional independency (after multivariate adjustment) was seen in the 
occluded subgroup compared to the non-occluded subgroup. A smaller study 
based on 72 patients has previously compared an 8-point increase in the baseline 
NIHSS with the presence of a large arterial occlusion, both carrying a similar 
prognostic value for functional dependency (OR 4·68). Our findings from a 
subgroup analysis confirm the independent predictive value of baseline arterial 
occlusions for predicting a poor functional outcome. 
One interesting finding from this study was the lowering of NIHSS thresholds 
for both predicting arterial occlusions as well as long-term functional outcome 
with increasing time from stroke onset to imaging. Regarding arterial occlusions, 
this may be explained by improved collateral blood-flow following occlusion, as 
well as some degree of spontaneous yet partial recanalization. The movement of 
a proximal thrombus to a more distal vessel may also play a role. The time 
dependence of NIHSS thresholds for predicting 3-months favourable outcome 
(mRS 0-2) may be explained by an accelerating transformation from penumbra 
to infarct, each NIHSS level bearing a worse prognosis due to less reversibility of 
the underlying ischaemia. This time dependency has previously been shown for 
NIHSS thresholds predicting arterial occlusions (51, 52), however to our 
knowledge this has not been shown regarding prediction of long-term functional 
outcome.  
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To conclude, we propose that patients with NIHSS levels above our cut-offs need 
to be identified, especially when vessel imaging is not available, as these patients 
show both a higher rate of arterial occlusions as well as a lower rate of a 
favourable 3-months outcome despite iv-tPA. Considering the time-dependency 
of the procured thresholds, a NIHSS score threshold of 9 or 10 may be considered 
for immediate referral to tertiary centres with endovascular capabilities. 
 
5.1.1 Study limitations 
Our results are based on a large cohort of patients from over 40 different 
countries, and should therefore be generalizable to clinical practice across 
various demographics and geographies. However, it is based on a retrospective 
and explorative analysis of observational data, with all the limitations of this type 
of study design. Important drawbacks of register based studies include 
difficulties in ascertaining unbiased reporting, lack of confounder information, 
absence of important data, loss to follow up and variations in coding between 
persons and institutions.  
Multivariate adjustment for differences in demographics and patient 
characteristics may not account for all imbalances. The amount of missing data 
for 3 month follow-up of the mRS (22.5%) may carry a bearing on our results. 
Another important limitation is the absence of specified site of vascular 
occlusion in our dataset, the pooling of proximal and more distal occlusions may 
have influenced the results of this study. Further, angiography data were only 
available in a subgroup of the patient population, probably resulting in inherent 
bias due to a highly-selected subgroup. Important to note however, the size of 
our patient cohort as well as the representation of general stroke patients from 
nearly 800 centres from different geographical locations, increases the 
generalizability of our results.  
 
5.1.2 Post-publication developments 
The ground-breaking randomised trials proving the benefit of endovascular 
thrombectomy in anterior acute ischaemic stroke with LAO were presented and 
published after the submission of this article to the International Journal of 
Stroke. Although endovascular treatment in AIS was performed in selected 
tertiary centres already prior to these trials, their results settled a controversy, in 
part due to previous negative studies, regarding the benefits of this new 
treatment modality. In light of this, the importance of identifying patients likely 
harbouring vessel occlusions amenable to endovascular intervention is further 
made more evident, and the results of this study add important knowledge for 
this identification. A major limitation of the present study was the inability to 
separate proximal arterial occlusions amenable to endovascular treatment from 
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more peripheral occlusions. After the publication of this paper, a German group 
attempted to replicate our results on a single-centre thrombolysis cohort, where 
site of occlusion was specified. They found a similar threshold as our study, 
NIHSS³10, for predicting proximal vessel occlusion (AUC 0.77, sensitivity 76·3%, 
specificity, 76·5%, NPV 81·5% and PPV 70·5%) (301), confirming our findings. A 
Danish study published at the same time as this study presented the results from 
their unselected cohort of acute ischaemic stroke patients evaluated within 4.5h, 
and found NIHSS³7 as the best cut-off for prediction of arterial occlusion in the 
anterior circulation within 4.5h (59). The median NIHSS in this cohort was 
substantially lower than in our cohort (NIHSS 10 in occluded patients and 3 in 
patients without visible occlusions), in line with the unselected nature of this 
cohort. This study included more peripheral cerebral artery occlusions (M2, 
ACA) in the definition of arterial occlusion, in contrast to the mentioned 
German study which only included more proximal occlusions. The more 
selective definition employed in the German study is in line with the inclusion 
criteria of the majority of the newly published RCTs on endovascular 
thrombectomy in AIS. 
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5.2 STUDY 2 
This study is to date the largest external validation attempt of ASTRAL and 
DRAGON, the 2 most recent outcome prediction scores in acute stroke. 
Extensive validation is a prerequisite for clinical implementation of a prognostic 
tool. Both scores have been validated previously, however to our knowledge the 
ASTRAL has not prior to this study been validated in an iv-tPA-treated cohort 
(268, 302, 266, 267). In this study, both scores showed promising performance 
with some limitations. The ASTRAL and DRAGON scores showed an acceptable 
or fair discriminative performance separating functional independency (mRS 0–
2) from functional dependency (mRS 3–6) in our cohort, with AUC-receiver 
operating characteristic values of 0.79 and 0.77 respectively. Despite some 
differences, discussed below, the overall visual and numeric trend and 
concurrence between the predicted and the actual outcomes in the calibration 
plots are promising. The largest discrepancy between predicted and actual 
outcome, comparing SITS-ISTR with the ASTRAL and DRAGON original 
cohorts, amounted to 11% and 17% respectively (larger discrepancies for ASTRAL 
at scores >46, but patient data here were limited). To facilitate the 
understanding of the current results we will now separate the discussion of the 
two scores, concluding with an overall discussion. 
ASTRAL- With increasing ASTRAL score cut-offs, increasing likelihood ratios 
for a poor outcome were seen in both the original ASTRAL cohort as well as in 
the SITS-ISTR. The main difference between the SITS-ISTR and ASTRAL cohorts 
was a higher proportion of functional dependency at 3 months in SITS-ISTR, 
most likely explained by a higher stroke severity in SITS-ISTR compared to 
ASTRAL (NIHSS 12 vs 9). All parameters of the ASTRAL score apart from visual 
field defects were significantly associated with functionally dependent outcome 
in our material. The two parameters showing the largest discrepancy between 
our data and the original ASTRAL cohort were level of consciousness and onset-
to-admission time. The difference in the regression coefficients for onset-to-
admission between the 2 cohorts is expected, as thrombolysed patients in SITS-
ISTR would be expected to arrive much earlier than the original unselected 
ASTRAL cohort. Regarding the differences in absolute magnitude of the 
regression coefficients for a low level of consciousness, one possible explanation 
could be that a larger proportion of patients in the ASTRAL cohort with a low 
level of consciousness arrive outside the time frame for thrombolysis, missing 
the opportunity for acute revascularization therapy and subsequent 
improvement. The difference in outcome between the patients with a low level 
of consciousness and alert patients could thus potentially become magnified in 
the ASTRAL compared to SITS cohorts. The differences in stroke severity is 
probably caused by the higher inclusion of patients with mild strokes in the 
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original ASTRAL cohort, explaining the higher proportion of favourable 
outcome in the ASTRAL cohort when compared with the SITS cohort (66% 
versus 57.4%).  
DRAGON- With increasing score cut-offs, lower likelihood ratios for favourable 
outcome were seen in both the SITS-ISTR and original DRAGON cohort. The 
main differences between the SITS-ISTR and DRAGON cohorts were: higher 
baseline stroke severity, lower proportion of early infarct signs and higher onset 
to treatment time in the SITS material. Despite these differences in baseline 
characteristics, all parameters of the DRAGON score were significantly 
associated with the outcome in the SITS-ISTR. The regression coefficients were 
relatively similar too, the biggest differences seen in age³80 and onset-to-
treatment time. The difference in regression coefficient for onset-to-treatment 
time could be caused by the baseline difference between the two cohorts with 
regard to this parameter.  
Comparing the ASTRAL and DRAGON scores, the DRAGON parameters have 
an overall better fit to the SITS-ISTR cohort, suggesting a better prognostic value 
of the DRAGON score compared to the ASTRAL score. However, both the 
ASTRAL and the DRAGON show an acceptable prognostic value considering 
both the calculated AUCs and the visual assessment of the calibration plots. 
Most interestingly, we were surprised that the discriminative performance of the 
ASTRAL, developed in an unselected ischaemic stroke cohort, differed so little 
from the DRAGON score, which was developed using a thrombolysis cohort. 
Intuitively, we had expected ASTRAL to underestimate good outcome and have 
a weaker performance in our thrombolysis cohort, but both showed a similar 
discriminative performance.  
Apart from conveying prognostic information to patients and caregivers early 
on, as well as a use for patient selection in RCTs, both scores may serve a 
potential use in the acute clinical setting. In settings without 24/7 access to 
multimodal imaging, both scores could be used to identify which patients who 
despite iv-tPA have a high probability of an unfavorable outcome (i.e. high 
scores). Both scores are heavily weighted by stroke severity measured on the 
NIHSS, and important correlations between increasing stroke severity and the 
presence of LAO have been described previously, as well as in the 1st and 3rd 
studies of this thesis. Therefore, high-score patients could be expected to 
harbour an increased proportion of LAO, suggesting transfer to tertiary centres 
with endovascular treatment capabilities. Prior to clinical implementation, we 
would need to prospectively validate the models to confirm the association 
between increased scoring and the presence of large vessel occlusions, as well as 
confirm the benefit of endovascular treatment in these selected patients. 
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In conclusion, our study has validated two of the most recently published stroke 
outcome prognostication tools and confirms their acceptable predictive value. 
Before clinical implementation of these scores, prospective evaluation of the 
impact of their use on patient outcomes after intravenous thrombolysis and 
mechanical thrombectomy are needed. 
  
5.2.1 Study limitations 
For general limitations of the SITS-ISTR cohort, please refer to section 5.1.1. One 
limitation specific for this study was that patients with basilar artery occlusion 
were excluded from the original DRAGON study. Site of occlusion was 
unfortunately not registered in our database. We were therefore not able to 
identify and exclude these patients, potentially affecting the predictive capability 
of the DRAGON score presented in this study. 
 
5.2.2 Post-publication developments 
After publication of this study, a most interesting paper was published in the 
European Journal of Neurology (303). This study invited physicians interested in 
stroke to provide outcome estimates in 720 real-life acute ischaemic stroke 
clinical scenarios, comparing the estimated outcome with that of the DRAGON 
and ASTRAL scores. Regarding unfavourable functional outcome (mRS>2), 
56.8% of physicians made a correct assessment, as compared to 86.5% of 
ASTRAL score estimates. Regarding catastrophic outcome (mRS 5-6), 24.8% of 
physicians made a correct estimation in comparison to 37.3% of DRAGON score 
estimates.  
In conclusion, ASTRAL and DRAGON both predicted with a higher accuracy 
compared to stroke physicians. In addition, at the ESOC 2016 stroke conference 
in Barcelona, the results of a new validation of the ASTRAL score was presented, 
assessing performance across stroke etiological subtype, showing a high 
accuracy of the score in predicting 3-month favourable outcome across all 
TOAST subtypes (304).     
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5.3  STUDY 3 
In this study, we show that although increasing numbers of included NIHSS sub-
items in LAO prediction models lead to better prediction, the differences do not 
seem to be clinically relevant. A simple predictive model only including an 
assessment of degree of arm motor dysfunction, derived from the NIHSS, shows 
sensitivities, specificities, PPVs and NPVs (69%,70%,68% and 70% respectively) 
similar to the values for an adjusted model including the full range of NIHSS 
sub-items (74%,72%, 71% and 73% respectively).  
 
Different settings and situations may need different trade-offs between 
sensitivity and specificity. In certain cases, a high specificity may be preferred, 
while another situation warrants a high sensitivity. These decisions are 
dependent on factors such as time remaining in the thrombolysis time window, 
as well as transport distances to secondary vs tertiary stroke centres. Using a 
high sensitivity model with an unadjusted cut-off NIHSS item 5 (arm function) 
≥ 2, gave a sensitivity, specificity, PPV and NPV of 79%, 55%, 63% and 73%, 
similar to the adjusted full-item NIHSS model, which gave a sensitivity, 
specificity, PPV and NPV of 80 %, 60%, 65% and 76% respectively. This 
corresponds to a cut-off of the total NIHSS score ≥ 10. Using a high specificity 
model with an unadjusted cut-off NIHSS item 5 (arm function) = 4 gave a 
specificity, sensitivity, PPV and NPV of 79%, 55 %, 71% and 65%, not very far 
from the adjusted full-item NIH model which gave a specificity, sensitivity, PPV 
and NPV of 80%, 64 %, 75% and 69%. This corresponds to a cut-off of the total 
NIHSS score ≥ 15. 
In summary, our simple arm-dysfunction model performs reasonably well in 
both clinical scenarios. 
 
Addition of clinical parameters other than the NIHSS sub-items to the models 
do not substantially change the predictive value. For each sub-item model, 
addition of other relevant predictors of LAO (the adjusted models) resulted in a 
model with a similar or slightly worse predictive value as compared to the simple 
addition of another NIHSS sub-item. The dominance of the NIHSS over other 
baseline clinical predictors in LAO prediction has been shown previously (297). 
 
Prediction of LAO without vessel imaging will always lead to either missing 
patients harbouring a treatable arterial occlusion, or unnecessary transfer of 
patients without treatable occlusions to comprehensive stroke centres. 
However, simple prediction rules may improve patient selection and potentially 
lead to improved onset to reperfusion times. Using the high-specificity cut-off 
(NIH item 5 = 4) as a triage tool to endovascular centres would identify roughly 
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40% of our study population as possible LAO candidates, the PPV amounting to 
71%, i.e. 7/10 successful transfers. Using the high-sensitivity cut-off (NIH item 5 
≥ 2) as a triage tool would identify roughly 60% of our study population, the PPV 
amounting to 63%, i.e. 6/10 successful transfers. The choice of cut-off depends 
on the clinical situation and local circumstances as outlined above. We suggest 
that a screening for severity of arm motor function can be used as an LAO 
screening step after confirmation of likely stroke diagnosis has been performed 
using a good stroke recognition score at the primary screening step, such as the 
FAST score (305). 
 
In conclusion, although increasingly more complex clinical models yield a higher 
discriminative performance for predicting LAO, the differences compared to 
very simple models are not large. Balancing predictive performance against ease 
of use and practicality, simply assessing the grade of arm dysfunction may serve 
as a surrogate measure of LAO status in anterior circulation stroke, and in 
conjunction with a validated stroke recognition instrument, may assist in 
decision making in guiding high-risk patients to comprehensive stroke centres 
with endovascular treatment capabilities. 
 
5.3.1 Study limitations 
For general limitations of the SITS-ISTR cohort, please refer to section 5.1.1. 
Although we propose to extend our results to a prehospital setting, assessments 
of the NIHSS registered in the database were performed in a hospital setting. 
Also, our study is based on patients treated with iv-tPA and/or endovascular 
thrombectomy and may not be valid for unselected patients with a prehospital 
suspicion of stroke. Our selection of iv-tPA treated patients is a potential source 
of bias, as haemorrhagic stroke patients will be a part of the assessed population 
in the prehospital phase. 
 
5.3.2 Post-publication developments 
At the time of submission of the thesis for printing, this manuscript is under 
review.  Therefore, no new data are available for discussion. 
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5.4 STUDY 4 
The modified Rankin Scale is the most common long-term outcome assessment 
tool in both clinical trials as well as in routine clinical follow-up after stroke. 
Routine clinical follow-up after stroke is lacking in many countries, partly due 
to limitations in resources and time-restraints.  
In this study, we show the possibility of using a mobile phone-based 
questionnaire for automatic assessment of functional outcome after stroke, 
which performed excellent in comparison with clinical visit mRS assessments. 
An excellent weighted kappa of 0.89 was seen for the main outcome assessing 
reliability for the whole spectrum of functional outcome, comparing mobile 
phone based self-assessments with an overall clinical assessment. Results were 
similar comparing the mobile phone-based method with a structured clinical 
assessment. A good interrater variability unweighted kappa (0.66) was found for 
the dichotomized analysis separating independent (mRS score 0–2) from 
dependent functional outcome (mRS score 3–5). 
Our results are in line with previous studies studying inter-rater reliability of 
mRS between healthcare professionals (306, 168). A systematic review, including 
10 studies on mRS reliability, found a combined unweighted kappa of 0.46 and 
weighted kappa of 0.90 for a traditional mRS assessment (166). Our results show 
an overall better inter-rater variability than these combined data, considering 
both the weighted and unweighted kappa. 
Common methods used for assessment of mRS include face-to-face interviews, 
telephone interviews, case sheet reviews, postal surveys, questionnaires and 
structured interviews (307). The most common methodology is probably face-
to-face interviews. 
Studies validating the performance of alternative assessment methodologies are 
limited. A couple of studies have investigated the role of mRS telephone 
assessment with mixed results (172, 173, 176-178). One study found a poor 
agreement when comparing telephone interviews with face-to-face interviews, 
with an un-weighted kappa value of 0.30-0.38 (172). Other studies have found 
more promising results with higher weighted kappa results, ranging from 0.71-
0.89 (176, 178). Yet the same studies show relatively low un-weighted kappa 
results close to 0.4. 
One study assessed the role of mRS derivation using case records from standard 
hospital records compared to face-to-face interviews, showing poor results (179). 
Another study assessed the performance of a simplified mRS questionnaire 
(smRSq) displayed a promising weighted kappa of 0.82 between two raters using 
the smRSq (180). The smRSq was further tested in a study comparing postal 
questionnaires based on the smRSq with telephone RFA-based assessments. 
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Agreement between postal smRSq and telephone interview was weighted kappa 
=0.73 and unweighted kappa=-0.55 (181). A major limitation of the smRSq studies 
is the lack of validation of the new proposed methods, the studies assessing 
reliability but merely assuming validity and not comparing with traditional face-
to-face mRS assessments. 
 
Our alternative assessment, a mobile phone–based questionnaire answered by 
either the patient or a close relative/caregiver, with the response automatically 
translated into an mRS rating, resulted in an excellent weighted kappa value of 
0.89 when compared with clinical visit face-to-face interviews. Only 15 out of 
totally 89 patients (17%) could not participate in the study because of lacking 
access to a compatible mobile phone, suggesting a high penetration of 
compatible mobile phone use in the general Swedish population, in all age 
groups. This novel form of assessment requires practically no time or resource 
allocation from the healthcare system because the patient/caregiver responses 
automatically can be converted into an mRS score without the need for 
professional score judgment.  
In conclusion, our findings suggest that mobile phone–based questionnaires 
may serve a supplementary role to traditional clinical visit assessments.  In 
settings where clinical visit follow-up assessments are scarce because of 
limitations in infrastructure and resources, this novel form of assessment may 
find an especially important role.  
 
5.4.1 Study limitations  
One important limitation of the current study is the relatively small size of the 
study cohort. Although we did not perform a formal power calculation, the study 
is of a similar size as the median of previously conducted studies on mRS 
interrater variability. The results need to be replicated in a larger multicentre 
setting before clinical implementation. A large confirmatory study is currently 
being planned, study enrolment starting by the end of 2017. In some cases, the 
analysis is based on answers from patients, and in other cases from relatives. This 
could affect the interpretation of the results, as patients participating and 
answering by themselves had milder strokes (median NIHSS 2 versus 7.5) and 
were younger (55 versus 73) compared to patients in whom a relative/caregiver 
answered the questionnaire. This however, reflects the real-life clinical situation. 
Elderly and more disabled patients may, due to various reasons, have difficulties 
using mobile phones. The proxy option is necessary to maximize follow up data, 
and encouragingly kappa values for the caregiver and patient responses analyzed 
separately were similar, suggesting the feasibility of using caregiver responses as 
a proxy for patient responses. The original RFA encourages eliciting information 
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from several sources, including patients, caregivers, physiotherapists, medical 
records etc.  A future improvement of the methodology used in this study could 
be to encourage patients to answer the questionnaire together with a relative or 
caregiver.  
 
5.4.2 Post-publication developments 
The modified Rankin Scale is the most common assessment of functional 
outcome used in clinical stroke trials, decisions on the effectiveness of new 
therapeutic agents being based on this final outcome measurement. Measures 
for improving reliability, as well as increasing follow-up in routine clinical 
follow-up should be highly prioritized. It is thus somewhat disconcerting that 
studies investigating methods of improving and increasing follow-up 
assessments are relatively scarce. Since the publication of this study, few studies 
have been published investigating outcome assessment after stroke. One 
interesting study by the REVASCAT investigators examined the feasibility and 
reliability of central video adjudication of 3 month modified Rankin Scale as well 
as telephone interviews compared to local evaluation by certified investigators. 
Using local evaluation as a reference, central video adjudication performed 
better than telephone interviews (weighted kappa 0.92 vs 0.77). In conclusion, 
the authors stated that central video adjudication was feasible and probably 
preferable to local-site assessments in clinical trials, avoiding potential problems 
related to lacking of blinding (308). Finally, a new version of the Rankin Focused 
Assessment was recently published with a small alteration in the wording of 
wheelchair mobility, RFA-A, which could be used in settings in which trialists 
wish to focus less on handicap (309). 
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Forecasting the outcomes of patients with various diseases is a cumbersome task 
since they depend on several factors, many often unknown at the time of 
prognostication. Nonetheless, a number of prognostic models have found their 
firm place in modern-day clinical practice, two examples being the “ABCD” and 
CHADS-VASc scores, both predicting the risk of ischaemic stroke following 
transient ischaemic attacks and atrial fibrillation respectively. 
As to prediction after an established stroke, whether concerning the presence of 
large-arterial occlusions and hyper-acute management on the one hand, or long-
term outcome on the other hand, no model has yet gained any widespread use. 
Reasons for this could at least partly be due to a seemingly impossible 
compromise between the complexity and wide variance in phenotype of injured 
human brains and the need for simplicity in score-prognostication for 
widespread use. However, based on the large empirical knowledge that 
randomised clinical trials and vast registry-based data have made available to us, 
prognostic models and tools have been developed. Despite this availability, 
which could assist in prognostication, they are infrequently used in clinical 
practice. Instead, individual physicians often communicate prognosis based on 
personal experiences and views.  
 
As to prediction of large-arterial occlusion in the setting of acute ischaemic 
stroke, now amenable to a proven highly effective treatment, several models 
have been proposed, the absolute majority including some measure of stroke 
severity as the most important prognostic variable. The accuracy of these mostly 
simple models or stroke severity thresholds are generally quite promising. 
Despite a relatively favourable accuracy, in many cases probably better than our 
clinical assessment, their use has not yet been widely supported by large 
neurological or neurovascular societies. North American societies are silent in 
the issue, only recently did the European Stroke Organization support a 
statement from the ESO Karolinska Stroke Update Consensus meeting, stating 
that an NIHSS threshold of ³9 within 3h of stroke onset could indicate the 
presence of a large arterial occlusion in the absence of non-invasive arterial 
imaging. Swift prehospital decision making could probably increase the number 
of patients offered endovascular treatment, with improvements in post-stroke 
functional level and potentially vast socio-economic effects. Triage based on the 
likelihood of patients harboring large arterial occlusions has not undergone any 
prospective large pre-hospital validation yet. The results from a large planned 
prehospital triage study on identifying large arterial occlusions in acute stroke 
starting in the Stockholm area in Sweden later this year will shed much needed 
light on the issue. Similar studies are planned/ongoing in the southern part of 
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Sweden. In the third project of this thesis, we present a simple arm paresis model 
for prediction of large-arterial occlusions in the acute setting of stroke. This 
model has a similar prognostic ability compared to the previously published 
models. It is the to date simplest model presented, and I believe that simplicity 
and ease of use are factors that are important in deciding the fate of all proposed 
models. 
As to predicting functional outcome after stroke, numerous models have been 
proposed as well, many with decent prognostic abilities spanning AUCs´ of 0.7-
0.8, a few compared to and shown to be superior to lone individual physician 
assessment. Their use could span from tools assisting in the communication with 
patients and care-givers to methods for patient selection in randomised trials 
and control for cohort composition in non-randomised trials. Despite a potential 
beneficial role, they have not gained any widespread use, neither in clinical 
practice nor in research settings. The first three projects of this thesis have 
sought to shed more light on the field of prognostication in acute ischaemic 
stroke. The final project has investigated the role of a novel method for 
increasing follow-up of functional outcome after acute stroke. 
Based on the results generated in this thesis, we have drawn the following 
conclusions: 
 
1) NIHSS thresholds can simultaneously predict both the presence of arterial 
occlusions as well as long-term functional outcome in acute ischaemic 
stroke. Considering an observed lowering of thresholds with increasing time 
delay from stroke onset to imaging, a threshold NIHSS score of 9 or 10 may 
be considered for immediate patient referral to comprehensive centres with 
endovascular capabilities, identifying patients with a higher risk of large 
arterial occlusion and poor outcome despite iv-tPA. The threshold is likely 
not optimal for use in the prehospital setting, considering the relative 
complexity of the NIH stroke scale. However, in the communication between 
centres with a limited availability of vascular imaging, and tertiary centres, it 
may serve an important role. Prior to clinical implementation, such a 
threshold would need further validation in independent cohorts. If the 
prognostic ability is confirmed and deemed sufficient, the threshold would 
subsequently need to undergo clinical evaluation during a test period, 
comparing threshold based decisions of transfer with pre-existing policies. 
 
2) Existing stroke prognostication models predict stroke outcome with a 
sufficient accuracy. Choice of model depends on the specific clinical query 
under investigation, but in the end, will need to show an improved patient 
outcome following their use for wide-spread implementation. I believe that 
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the field of stroke outcome prognostication deserves increased attention. 
Illuminating the benefits and potential pitfalls of a wider use of these models 
should be of interest to the stroke community. A suitable setting could be 
focused discussions at future international consensus meetings or 
conferences. 
 
3) In the prehospital setting, simple models predicting the presence of large 
arterial occlusions amenable to endovascular intervention may facilitate 
triage decisions, potentially reducing time to recanalization in selected 
patients. Increasingly more complex clinical models yield a slightly higher 
discriminative performance for predicting LAO, however, the difference 
compared to extremely simple models is not large. Balancing predictive 
performance against ease of use and practicality, simply assessing the grade 
of arm dysfunction may serve as a surrogate measure of LAO status in 
anterior circulation stroke, and in conjunction with a validated stroke 
recognition instrument may assist in decision-making in guiding high-risk 
patients to comprehensive stroke centres with endovascular treatment 
capabilities. Our proposed model needs extensive validation in independent 
cohorts prior to clinical testing. A planned prehospital triage study using a 
similar hemiparesis model will commence within shortly in the Stockholm 
area in Sweden. Depending on the primary interim results from this study 
our arm-paresis model could serve as a simpler alternative, with retained 
prognostic ability. 
 
4) Self-assessment of functional outcome as measured by modified Rankin Scale 
based on a mobile phone application questionnaire performs well compared 
to routine in-clinic assessments. Mobile phone–based questionnaires may 
serve a supplementary role to clinical visit assessments, especially in settings 
where clinical follow-up visits are scarce because of economic and time-
restraining factors. A larger confirmatory study is planned and will start 
recruitment later this year. 
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